

A Randomized, Controlled Trial of Ebola Virus Disease T

New England Journal of Medicine

381, 2293-2303

DOI: [10.1056/nejmoa1910993](https://doi.org/10.1056/nejmoa1910993)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Monoclonal Antibody Therapy for Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2019, 381, 2365-2366.	13.9	52
2	Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. <i>Microbes and Infection</i> , 2020, 22, 119-126.	1.0	10
3	Association between treatment with oral third-generation cephalosporin antibiotics and mortality outcomes in Ebola virus disease: a multinational retrospective cohort study. <i>Tropical Medicine and International Health</i> , 2020, 25, 433-441.	1.0	2
4	Antibodies to watch in 2020. <i>MAbs</i> , 2020, 12, 1703531.	2.6	381
5	Run, Hide, Fight, or Secure, Preserve, Fight: How Should Health Care Professionals and Facilities Respond to Active Shooter Incidents?. <i>Academic Emergency Medicine</i> , 2020, 27, 252-255.	0.8	1
6	Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa345.	0.4	28
7	Response to Letter. <i>Obstetrics and Gynecology</i> , 2020, 136, 429-430.	1.2	0
8	Overview of coronavirus disease 2019: Treatment updates and advances. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 805-808.	0.6	10
9	COVID-19 and HIV. <i>Colombia Medica</i> , 2020, 51, 1-10.	0.7	3
10	Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 226.	1.6	12
11	Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104583.	1.0	11
12	Effects of SARS-CoV-2 and its functional receptor ACE2 on the cardiovascular system. <i>Herz</i> , 2020, 45, 659-662.	0.4	4
13	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. <i>British Journal of Biomedical Science</i> , 2020, 77, 168-184.	1.2	12
14	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1999-2010.	1.2	23
15	The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. <i>Biochimie</i> , 2020, 179, 85-100.	1.3	172
16	COVID-19 in the Pediatric Population—Review and Current Evidence. <i>Current Infectious Disease Reports</i> , 2020, 22, 29.	1.3	32
17	Nanomedicine strategies to target coronavirus. <i>Nano Today</i> , 2020, 35, 100961.	6.2	48
18	Engineering Antiviral Vaccines. <i>ACS Nano</i> , 2020, 14, 12370-12389.	7.3	50

#	ARTICLE	IF	CITATIONS
19	Selectivity over coverage in <i>de novo</i> sequencing of IgGs. <i>Chemical Science</i> , 2020, 11, 11886-11896.	3.7	13
21	Current treatment of COVID-19 in renal patients: hope or hype?. <i>Internal and Emergency Medicine</i> , 2020, 15, 1389-1398.	1.0	9
22	Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26946-26954.	3.3	54
23	A Review of Remdesivir for COVID-19: Data to Date. <i>Cardiology in Review</i> , 2020, 28, 332-334.	0.6	9
24	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e3996-e4004.	2.9	90
25	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. <i>Trends in Immunology</i> , 2020, 41, 1006-1022.	2.9	79
26	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <i>Frontiers in Pharmacology</i> , 2020, 11, 585888.	1.6	11
27	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26915-26925.	3.3	104
28	Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	181
29	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <i>Immunobiology</i> , 2020, 225, 152008.	0.8	65
30	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. <i>Advances in Biomarker Sciences and Technology</i> , 2020, 2, 1-23.	0.8	79
31	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. <i>Computational Biology and Chemistry</i> , 2020, 89, 107372.	1.1	30
32	Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105522.	1.9	25
33	The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. <i>Virology</i> , 2020, 551, 1-9.	1.1	179
34	An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. <i>Journal of Infection and Public Health</i> , 2020, 13, 1405-1414.	1.9	38
35	Machine learning for clinical trials in the era of COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 506-517.	0.6	40
36	US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue. <i>BMJ, The</i> , 2020, 370, m2797.	3.0	6
37	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 2304-2318.	1.8	42

#	ARTICLE	IF	CITATIONS
38	Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?. Pathology Research and Practice, 2020, 216, 153086.	1.0	33
39	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. British Journal of Haematology, 2020, 190, e274-e276.	1.2	20
40	Clinical trials in the time of a pandemic. Clinical Trials, 2020, 17, 467-471.	0.7	5
41	Current strategies against COVID-19. Chinese Medicine, 2020, 15, 70.	1.6	15
42	Immune response in COVID-19: A review. Journal of Infection and Public Health, 2020, 13, 1619-1629.	1.9	281
43	New WHO guidelines on the management of pregnancy and breastfeeding in the context of Ebola. Lancet Infectious Diseases, The, 2020, 20, 766-767.	4.6	3
44	Guidance for the management of adult patients with coronavirus disease 2019. Chinese Medical Journal, 2020, 133, 1575-1594.	0.9	20
45	Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. Antiviral Research, 2020, 181, 104863.	1.9	16
46	The epidemiology and therapeutic options for the COVID-19. Precision Clinical Medicine, 2020, 3, 71-84.	1.3	17
47	Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical Trials, 2020, 17, 472-482.	0.7	55
48	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. International Journal of Molecular Sciences, 2020, 21, 4953.	1.8	41
49	In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Research, 2020, 181, 104878.	1.9	114
50	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discovery, 2020, 25, 1141-1151.	1.4	131
51	Pathogenesis and management of myocardial injury in coronavirus disease 2019. European Journal of Heart Failure, 2020, 22, 1994-2006.	2.9	33
52	Known drugs and small molecules in the battle for COVID-19 treatment. Genes and Diseases, 2020, 7, 528-534.	1.5	14
53	The Ebola outbreak in the Democratic Republic of the Congo: why there is no "silver bullet". Nature Immunology, 2020, 21, 591-594.	7.0	29
54	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 483-497.	0.6	40
55	Bioengineered <i>in Vitro</i> Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. ACS Biomaterials Science and Engineering, 2020, 6, 6540-6555.	2.6	20

#	ARTICLE	IF	CITATIONS
56	Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. <i>Seminars in Immunology</i> , 2020, 50, 101427.	2.7	31
57	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <i>Journal of Thoracic Disease</i> , 2020, 12, 6054-6069.	0.6	14
58	Repurposing Pyramax [®] , quinacrine and tilorone as treatments for Ebola virus disease. <i>Antiviral Research</i> , 2020, 182, 104908.	1.9	20
59	Drug-Drug, Drug-Disease and Disease-Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs). <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2020, 5, 216-222.	0.1	0
60	Detection of Ebola virus from skin ulcers after clearance of viremia. <i>Journal of Clinical Virology</i> , 2020, 131, 104595.	1.6	0
61	COVID-19 Pandemic and Pregnancy in Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 397-403.	0.6	6
62	The Assessment of Convalescent Plasma Efficacy against COVID-19. <i>Med</i> , 2020, 1, 66-77.	2.2	17
63	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2716-2746.	2.9	149
64	Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis. <i>ERJ Open Research</i> , 2020, 6, 00562-2020.	1.1	0
65	FDA efficiency for approval process of COVID-19 therapeutics. <i>Infectious Agents and Cancer</i> , 2020, 15, 73.	1.2	8
66	Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2021, 35, 269-292.	1.7	12
67	Use of Chinese medicine in the prevention and treatment of COVID-19 in China and Asia. <i>Asian Education and Development Studies</i> , 2020, 10, 198-209.	1.3	2
69	Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection. <i>International Journal of Transgender Health</i> , 2020, 13, 608-614.	1.1	11
70	Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 884-888.	2.7	5
72	Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 737-741.	0.6	19
73	Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 768-770.	0.7	27
74	The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19): Remdesivir Is a Foot in the Door. <i>Clinical Infectious Diseases</i> , 2021, 73, e4175-e4178.	2.9	18
75	<p></p>A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19</p></p>Drug Design, Development and Therapy, 2020, Volume 14, 3215-3222.	2.0	44

#	ARTICLE	IF	CITATIONS
76	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. <i>Reviews in Medical Virology</i> , 2020, 30, 1-13.	3.9	25
77	Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1738-1748.	0.6	36
78	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24
79	Ebola, COVID-19, and emerging infectious disease: lessons learned and future preparedness. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 416-422.	1.3	9
80	Potential strategies for combating COVID-19. <i>Archives of Virology</i> , 2020, 165, 2419-2438.	0.9	12
81	Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1653-1658.	1.3	15
82	Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 39, 1-16.	2.0	23
83	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. <i>Food and Chemical Toxicology</i> , 2020, 144, 111639.	1.8	42
84	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. <i>Current Pharmacology Reports</i> , 2020, 6, 228-240.	1.5	17
85	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100159.	1.3	34
86	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020, 584, 120-124.	13.7	1,237
87	Drug Discovery Strategies for SARS-CoV-2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 127-138.	1.3	83
88	COVID-19 and the Kidneys: An Update. <i>Frontiers in Medicine</i> , 2020, 7, 423.	1.2	79
89	MARvellous Sidekick Antibodies. <i>Cell Host and Microbe</i> , 2020, 27, 856-858.	5.1	0
90	Remdesivir: Remedy the world is waiting for?. <i>Medical Journal Armed Forces India</i> , 2020, 76, 250-252.	0.3	0
91	Searching for COVID-19 treatments: First, do no harm. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1899-1905.	0.5	3
92	Diagnostic and Treatment Strategies for COVID-19. <i>AAPS PharmSciTech</i> , 2020, 21, 222.	1.5	31
93	Safety profile of the antiviral drug remdesivir: An update. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110532.	2.5	82

#	ARTICLE	IF	CITATIONS
94	Endo-Lysosomal Cation Channels and Infectious Diseases. Reviews of Physiology, Biochemistry and Pharmacology, 2020, , 259-276.	0.9	19
97	Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. Chemico-Biological Interactions, 2020, 332, 109298.	1.7	7
98	Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). Obstetrics and Gynecology, 2020, 136, 1025-1029.	1.2	37
99	Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven. Contemporary Clinical Trials Communications, 2020, 20, 100663.	0.5	0
100	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. BMJ, The, 2020, 371, m3869.	3.0	16
101	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Science Advances, 2020, 6, .	4.7	128
102	Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?. Bioanalysis, 2020, 12, 1325-1336.	0.6	7
103	Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. Reviews in Medical Virology, 2021, 31, e2187.	3.9	76
104	Intricate interplay between Covid-19 and cardiovascular diseases. Reviews in Medical Virology, 2020, 31, e2188.	3.9	9
105	Animal models for SARS-CoV-2 research: A comprehensive literature review. Transboundary and Emerging Diseases, 2021, 68, 1868-1885.	1.3	58
106	The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and Disease, 2020, 78, .	0.8	7
107	Remdesivir: First Approval. Drugs, 2020, 80, 1355-1363.	4.9	176
108	Bilateral posterior cerebral artery territory infarction in a SARS-Cov-2 infected patient: discussion about an unusual case. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105095.	0.7	11
109	Bibliometric Analysis of Ebola Research Indexed in Web of Science and Scopus (2010-2020). BioMed Research International, 2020, 2020, 1-12.	0.9	34
110	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy, 2020, 5, 212.	7.1	104
111	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open, 2020, 10, e041437.	0.8	46
112	Traditional Chinese Medicine as Potential Therapy for COVID-19. The American Journal of Chinese Medicine, 2020, 48, 1263-1277.	1.5	11
113	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. Pathogens and Disease, 2020, 78, .	0.8	17

#	ARTICLE	IF	CITATIONS
114	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3359-3365.	1.3	41
115	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 596-608.	0.6	29
116	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. <i>Processes</i> , 2020, 8, 937.	1.3	23
117	Protection by Exclusion: Another Missed Opportunity to Include Pregnant Women in Research During the Coronavirus Disease 2019 (COVID-19) Pandemic. <i>Obstetrics and Gynecology</i> , 2020, 136, 430-430.	1.2	1
118	Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect?. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 765-771.	0.6	11
119	Remdesivir, a remedy or a ripple in severe COVID-19?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1195-1198.	1.9	9
120	COVID-19 in Human, Animal, and Environment: A Review. <i>Frontiers in Veterinary Science</i> , 2020, 7, 578.	0.9	54
123	COVID-19: an update and cardiac involvement. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 239.	0.4	10
124	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 812-816.	0.6	14
125	Improvement of Severe COVID-19 in an Elderly Man by Sequential Use of Antiviral Drugs. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-4.	0.2	1
126	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. <i>Molecular Neurobiology</i> , 2020, 57, 4856-4877.	1.9	26
127	Marburg virus disease: A summary for clinicians. <i>International Journal of Infectious Diseases</i> , 2020, 99, 233-242.	1.5	67
128	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	1.6	65
129	Recent successes in therapeutics for Ebola virus disease: no time for complacency. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e231-e237.	4.6	42
130	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. <i>Antibody Therapeutics</i> , 2020, 3, 246-256.	1.2	34
131	Plant Molecular Farming as a Strategy Against COVID-19 – The Italian Perspective. <i>Frontiers in Plant Science</i> , 2020, 11, 609910.	1.7	15
132	Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. <i>Antiviral Chemistry and Chemotherapy</i> , 2020, 28, 204020662097678.	0.3	18
133	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. <i>Journal of Translational Medicine</i> , 2020, 18, 489.	1.8	13

#	ARTICLE	IF	CITATIONS
134	COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12004.	5.5	43
135	Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. <i>MAbs</i> , 2020, 12, 1854149.	2.6	126
136	Does remdesivir have any neuropsychiatric adverse effects?. <i>Irish Journal of Psychological Medicine</i> , 2021, 38, 313-314.	0.7	7
137	Osteopathic Considerations for the Pregnant Patient With COVID-19. <i>Journal of Osteopathic Medicine</i> , 2020, 120, 785-791.	0.4	0
138	Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics. <i>Cell</i> , 2020, 183, 1383-1401.e19.	13.5	79
139	Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. <i>Cell Host and Microbe</i> , 2020, 28, 638-645.	5.1	30
140	Marked Sinus Bradycardia Associated With Remdesivir in COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 2260-2264.	0.3	68
141	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. <i>Journal of Immunology Research</i> , 2020, 2020, 1-8.	0.9	26
142	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. <i>Frontiers in Pharmacology</i> , 2020, 11, 588654.	1.6	99
143	Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. <i>Pharmaceutics</i> , 2020, 12, 1031.	2.0	36
144	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	59
145	A current review of COVID-19 for the cardiovascular specialist. <i>American Heart Journal</i> , 2020, 226, 29-44.	1.2	97
146	Current targeted therapeutics against COVID-19: Based on first-line experience in China. <i>Pharmacological Research</i> , 2020, 157, 104854.	3.1	30
147	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. <i>ACS Central Science</i> , 2020, 6, 672-683.	5.3	684
148	Viral genomics in Ebola virus research. <i>Nature Reviews Microbiology</i> , 2020, 18, 365-378.	13.6	30
149	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	1.3	69
150	Medical treatment options for COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 209-214.	0.4	39
151	Antibody-based therapies for COVID-19: Can Europe move faster?. <i>PLoS Medicine</i> , 2020, 17, e1003127.	3.9	5

#	ARTICLE	IF	CITATIONS
152	COVID-19 “ What does a paediatrician need to know?. Paediatric Respiratory Reviews, 2020, 35, 3-8.	1.2	5
153	COVID-19 as an Acute Inflammatory Disease. Journal of Immunology, 2020, 205, 12-19.	0.4	133
154	The liver in times of COVID-19: What hepatologists should know. Annals of Hepatology, 2020, 19, 353-358.	0.6	72
155	Materials science approaches in the development of broad-spectrum antiviral therapies. Nature Materials, 2020, 19, 813-816.	13.3	36
156	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Annals of the American Thoracic Society, 2020, 17, 1008-1015.	1.5	27
157	COVID-19: An Update about the Discovery Clinical Trial. Pharmaceuticals, 2020, 13, 98.	1.7	10
158	SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review. Expert Opinion on Therapeutic Patents, 2020, 30, 567-579.	2.4	54
159	Ebola. New England Journal of Medicine, 2020, 382, 1832-1842.	13.9	128
160	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Military Medical Research, 2020, 7, 22.	1.9	57
161	A global treatments for coronaviruses including COVID-19. Journal of Cellular Physiology, 2020, 235, 9133-9142.	2.0	91
162	Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes and Infection, 2020, 22, 231-235.	1.0	44
163	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS ONE, 2020, 15, e0232757.	1.1	11
164	Rapid review for the anti-coronavirus effect of remdesivir. Drug Discoveries and Therapeutics, 2020, 14, 73-76.	0.6	48
165	Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). JAMA Pediatrics, 2020, 174, 825.	3.3	28
166	Covid-19 and drug therapy, what we learned. International Journal of Clinical Pharmacy, 2020, 42, 833-836.	1.0	11
167	Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. American Journal of Obstetrics & Gynecology MFM, 2020, 2, 100134.	1.3	297
168	Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda. Health Security, 2020, 18, 114-124.	0.9	4
169	Quercetin Blocks Ebola Virus Infection by Counteracting the VP24 Interferon-Inhibitory Function. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	41

#	ARTICLE	IF	CITATIONS
170	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. <i>Gastroenterology</i> , 2020, 159, 320-334.e27.	0.6	330
171	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
172	An overview of COVID-19. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 343-360.	1.3	318
173	Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, 1894-1901.	1.9	41
174	Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. <i>American Journal of Cardiology</i> , 2020, 128, 147-150.	0.7	33
175	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. <i>AAPS PharmSciTech</i> , 2020, 21, 130.	1.5	6
176	Current evidence for directed and supportive investigational therapies against COVID-19. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2020, 26, 45.	0.3	1
177	Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. <i>Drug Safety</i> , 2020, 43, 645-656.	1.4	54
178	Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. <i>AAPS Journal</i> , 2020, 22, 77.	2.2	98
179	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). <i>Pharmacological Research</i> , 2020, 158, 104929.	3.1	95
180	Potential specific therapies in COVID-19. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662092685.	1.0	18
181	<scp>SARSâ€CoVâ€2</scp> in the context of past coronaviruses epidemics: Consideration for prenatal care. <i>Prenatal Diagnosis</i> , 2020, 40, 1641-1654.	1.1	22
182	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1827-1837.	13.9	1,152
183	Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. <i>Virus Research</i> , 2020, 286, 198057.	1.1	57
184	Practice considerations on the use of investigational antiâ€COVIDâ€19 medications: Dosage, administration and monitoring. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1199-1205.	0.7	10
185	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 381-395.	0.4	43
186	Monoclonal Antibodies for Prevention and Treatment of COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 131.	3.8	237
187	Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection. <i>Cardiology and Therapy</i> , 2020, 9, 293-305.	1.1	11

#	ARTICLE	IF	CITATIONS
189	Possible therapeutic agents for COVID-19: a comprehensive review. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1005-1020.	2.0	24
190	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	6.0	1,104
191	nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 616.	1.8	56
192	SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. <i>Biochemical Pharmacology</i> , 2020, 178, 114114.	2.0	89
193	The National Institute of Allergy and Infectious Diseases Decision to Stop the Adaptive COVID-19 Trial. <i>JACC Basic To Translational Science</i> , 2020, 5, 645-647.	1.9	8
194	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. <i>Virus Research</i> , 2020, 286, 198070.	1.1	107
195	Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. <i>Molecules</i> , 2020, 25, 2784.	1.7	72
196	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112527.	2.6	85
197	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa232.	0.4	16
198	Systematic Review of Clinical Insights into Novel Coronavirus (CoVID-19) Pandemic: Persisting Challenges in U.S. Rural Population. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4279.	1.2	64
199	ACE2, Much More Than Just a Receptor for SARS-COV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 317.	1.8	276
200	Potential Treatments for SARS-CoV-2 Infection. <i>Clinical Liver Disease</i> , 2020, 15, 181-186.	1.0	6
201	Overview of therapeutic drug research for COVID-19 in China. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1133-1140.	2.8	38
202	Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature. <i>In Vivo</i> , 2020, 34, 1619-1628.	0.6	55
203	COVID-19: Drug Targets and Potential Treatments. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12359-12386.	2.9	348
204	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 2174-2187.	0.7	34
205	Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1384-1386.	3.0	142
206	<p><p>Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2159-2164.	2.0	11

#	ARTICLE	IF	CITATIONS
207	How likely are COVID-19 interventions to benefit the sickest patients?. Intensive Care Medicine, 2020, 46, 1441-1444.	3.9	3
208	Anti-HFRS Human IgG Produced in Transchromosomal Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models. Frontiers in Microbiology, 2020, 11, 832.	1.5	21
209	Coronavirus in pregnancy and delivery: rapid review. Ultrasound in Obstetrics and Gynecology, 2020, 55, 586-592.	0.9	390
210	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmunity Reviews, 2020, 19, 102523.	2.5	353
211	Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 75, 2352-2371.	1.2	1,557
212	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 2020, 30, 269-271.	5.7	5,527
213	Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses. Npj Vaccines, 2020, 5, 17.	2.9	17
214	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological Research, 2020, 156, 104761.	3.1	494
215	Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6771-6776.	3.3	735
216	SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens, 2020, 9, 231.	1.2	513
217	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. International Journal of Biological Sciences, 2020, 16, 1678-1685.	2.6	751
218	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 258-271.	1.3	20
219	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases, 2020, 7, ofaa105.	0.4	255
220	Drug repurposing strategies for COVID-19. Future Drug Discovery, 2020, 2, .	0.8	87
221	Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American Journal of Obstetrics and Gynecology, 2020, 222, 521-531.	0.7	893
222	Controversial treatments: An updated understanding of the coronavirus disease 2019. Journal of Medical Virology, 2020, 92, 1441-1448.	2.5	73
223	Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infectious Diseases, The, 2020, 20, 697-706.	4.6	953
224	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 2020, 46, 854-887.	3.9	1,536

#	ARTICLE	IF	CITATIONS
225	Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 740-746.	2.5	257
226	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. <i>New England Journal of Medicine</i> , 2020, 382, 1366-1369.	13.9	63
227	COVID-19: a new challenge for human beings. <i>Cellular and Molecular Immunology</i> , 2020, 17, 555-557.	4.8	313
228	Insight into 2019 novel coronavirus – An updated interim review and lessons from SARS-CoV and MERS-CoV. <i>International Journal of Infectious Diseases</i> , 2020, 94, 119-124.	1.5	337
229	It's not just science: Challenges for public health intervention in Ebola epidemics in the Democratic Republic of Congo. <i>Science China Life Sciences</i> , 2020, 63, 1079-1081.	2.3	4
230	Covid-19: a puzzle with many missing pieces. <i>BMJ, The</i> , 2020, 368, m627.	3.0	82
231	Remdesivir as a possible therapeutic option for the COVID-19. <i>Travel Medicine and Infectious Disease</i> , 2020, 34, 101615.	1.5	250
232	Further Considerations About the Ophthalmic Sequelae of Ebola. <i>JAMA Ophthalmology</i> , 2020, 138, 403.	1.4	0
233	Arguments in favour of remdesivir for treating SARS-CoV-2 infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105933.	1.1	263
234	Current pharmacological treatments for SARS-COV-2: A narrative review. <i>European Journal of Pharmacology</i> , 2020, 882, 173328.	1.7	35
235	SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2020, 49, 101846.	0.6	27
236	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2977-2980.	1.3	90
237	Remdesivir – Bringing Hope for COVID-19 Treatment. <i>Scientia Pharmaceutica</i> , 2020, 88, 29.	0.7	24
238	Conjunctivitis as a Sentinel of SARS-CoV-2 Infection: a Need of Revision for Mild Symptoms. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 859-864.	0.3	5
239	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106080.	1.1	149
240	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	36
241	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	2.9	412
242	In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies. <i>Emerging Microbes and Infections</i> , 2020, 9, 1523-1533.	3.0	9

#	ARTICLE	IF	CITATIONS
243	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	1.0	36
244	The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008259.	1.3	13
245	Emerging Prevention and Treatment Strategies to Control COVID-19. <i>Pathogens</i> , 2020, 9, 501.	1.2	22
246	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. <i>Vaccines</i> , 2020, 8, 335.	2.1	43
247	Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review. <i>BMC Medicine</i> , 2020, 18, 190.	2.3	30
248	Pregnancy and breastfeeding in the context of Ebola: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e149-e158.	4.6	30
249	Current therapies under investigation for COVID-19: potential COVID-19 treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 483-489.	0.7	6
250	Case report study of the first five COVID-19 patients treated with remdesivir in France. <i>International Journal of Infectious Diseases</i> , 2020, 98, 290-293.	1.5	30
252	Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100164.	1.3	24
253	Delayed recognition of Ebola virus disease is associated with longer and larger outbreaks. <i>Emerging Microbes and Infections</i> , 2020, 9, 291-301.	3.0	18
254	The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. <i>Journal of Biological Chemistry</i> , 2020, 295, 4773-4779.	1.6	659
255	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. <i>Viruses</i> , 2020, 12, 244.	1.5	552
256	Antibody Teamwork against Ebola Virus Disease. <i>Immunity</i> , 2020, 52, 217-219.	6.6	0
257	Transcriptional Correlates of Tolerance and Lethality in Mice Predict Ebola Virus Disease Patient Outcomes. <i>Cell Reports</i> , 2020, 30, 1702-1713.e6.	2.9	28
258	A Novel Coronavirus (COVID-19) Outbreak. <i>Chest</i> , 2020, 157, e99-e101.	0.4	63
259	Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.	18.1	340
260	Prior vaccination with recombinant Vesicular Stomatitis Virus "Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection. <i>Vaccine</i> , 2020, 38, 3003-3007.	1.7	14
261	Treating Ebola in eastern DRC. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 284-285.	4.6	3

#	ARTICLE	IF	CITATIONS
262	Treatment of Ebola-related critical illness. <i>Intensive Care Medicine</i> , 2020, 46, 285-297.	3.9	15
263	Modeling Challenges of Ebola Virusâ€™Host Dynamics during Infection and Treatment. <i>Viruses</i> , 2020, 12, 106.	1.5	7
264	Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections. <i>Expert Review of Vaccines</i> , 2020, 19, 85-103.	2.0	4
265	In emergencies, health research must go beyond public engagement toward a true partnership with those affected. <i>Nature Medicine</i> , 2020, 26, 308-309.	15.2	2
266	First Case of 2019 Novel Coronavirus in the United States. <i>New England Journal of Medicine</i> , 2020, 382, 929-936.	13.9	4,773
267	Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. <i>Viruses</i> , 2020, 12, 92.	1.5	16
268	Clinical trials in an Ebola outbreak seek to find an evidence-based cure. <i>EBioMedicine</i> , 2020, 52, 102614.	2.7	5
269	Next-generation direct-acting influenza therapeutics. <i>Translational Research</i> , 2020, 220, 33-42.	2.2	43
270	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2020, 395, 1569-1578.	6.3	2,875
271	Remdesivir in covid-19. <i>BMJ, The</i> , 2020, 369, m1610.	3.0	91
272	Treatment Considerations for COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1454-1466.	1.4	79
273	<scp>ISUOG</scp> Interim Guidance on coronavirus disease 2019 (COVIDâ€™19) during pregnancy and puerperium: information for healthcare professionals â€™ an update. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 848-862.	0.9	80
274	Will the antimalarial drug take over to combat COVID-19?. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, , 1-4.	0.8	4
275	Candidate drugs against SARS-CoV-2 and COVID-19. <i>Pharmacological Research</i> , 2020, 157, 104859.	3.1	426
276	COVID-19 for the Cardiologist. <i>JACC Basic To Translational Science</i> , 2020, 5, 518-536.	1.9	256
277	Repurposing therapeutic agents and herbal medicines to defeat viral nemesis. <i>Drug Development Research</i> , 2020, 81, 641-642.	1.4	3
278	COVIDâ€™19: A review of therapeutics under investigation. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 231-237.	0.4	29
279	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. <i>Pharmacotherapy</i> , 2020, 40, 416-437.	1.2	166

#	ARTICLE	IF	CITATIONS
280	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. <i>Lancet Respiratory Medicine</i> , 2020, 8, 506-517.	5.2	1,177
281	Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105950.	1.1	131
282	The epidemiology, diagnosis and treatment of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105955.	1.1	672
283	SARS-CoV-2 Vaccines: Status Report. <i>Immunity</i> , 2020, 52, 583-589.	6.6	999
284	Treatment options for COVID-19: The reality and challenges. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 436-443.	1.5	393
285	Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. <i>One Health</i> , 2020, 9, 100128.	1.5	157
286	COVID-19: A promising cure for the global panic. <i>Science of the Total Environment</i> , 2020, 725, 138277.	3.9	464
287	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101647.	1.5	227
288	COVID-19, Patents and the Never-Ending Tension between Proprietary Rights and the Protection of Public Health. <i>European Journal of Risk Regulation</i> , 2020, 11, 390-395.	0.8	10
289	Compassionate Use of Remdesivir for Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 2327-2336.	13.9	2,241
290	Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. <i>Journal of Biological Chemistry</i> , 2020, 295, 6785-6797.	1.6	752
291	Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks. <i>Tissue Engineering - Part A</i> , 2020, 26, 468-474.	1.6	39
292	Infectious Disease Outbreaks: The Need For an All-in Approach. <i>Journal of Infectious Diseases</i> , 2020, 222, 1941-1942.	1.9	0
293	Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	335
294	Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. <i>MBio</i> , 2020, 11, .	1.8	147
295	Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses. <i>Molecules</i> , 2020, 25, 1800.	1.7	56
296	COVID-19: A Brief Overview of the Discovery Clinical Trial. <i>Pharmaceuticals</i> , 2020, 13, 65.	1.7	30
297	Pathogenesis of Uveitis in Ebola Virus Disease Survivors: Evolving Understanding from Outbreaks to Animal Models. <i>Microorganisms</i> , 2020, 8, 594.	1.6	4

#	ARTICLE	IF	CITATIONS
298	Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e147-e160.	2.0	37
299	A Review of SARS-CoV-2 and the Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2657.	1.8	530
300	First Case of Covid-19 in the United States. <i>New England Journal of Medicine</i> , 2020, 382, e53.	13.9	18
301	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1043-1049.	2.0	30
302	Anti-HIV agents inspired by antibodies. <i>Nature Chemical Biology</i> , 2020, 16, 483-484.	3.9	4
303	Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention. <i>Advanced Therapeutics</i> , 2020, 3, 2000034.	1.6	44
304	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. <i>Cardiovascular Pathology</i> , 2020, 47, 107228.	0.7	97
305	DÃ©jÃ© vu: Stimulating open drug discovery for SARS-CoV-2. <i>Drug Discovery Today</i> , 2020, 25, 928-941.	3.2	81
306	Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. <i>Nature Medicine</i> , 2020, 26, 861-868.	15.2	327
307	Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 1-10.	2.0	365
308	Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials. <i>Clinical Infectious Diseases</i> , 2020, 71, 879-881.	2.9	42
309	Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 701-715.	0.6	130
310	How should we treat pregnant women infected with SARSâ€CoVâ€2?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1050-1052.	1.1	8
311	Ethics of Conducting Clinical Research in an Outbreak Setting. <i>Annual Review of Virology</i> , 2020, 7, 475-494.	3.0	10
312	COVID-19 and neuromuscular disorders. <i>Neurology</i> , 2020, 94, 959-969.	1.5	233
313	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. <i>Cmaj</i> , 2020, 192, E405-E407.	0.9	36
314	Optimizing Hydroxychloroquine Dosing for Patients With COVIDâ€19: An Integrative Modeling Approach for Effective Drug Repurposing. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 253-263.	2.3	86
315	Delayed Initiation of Remdesivir in a COVIDâ€19â€Positive Patient. <i>Pharmacotherapy</i> , 2020, 40, 592-598.	1.2	59

#	ARTICLE	IF	CITATIONS
316	Improving the Evidence for New Interventions in Infectious Diseases: Refocusing on Patients Instead of Pathogens and Direct Evidence for Added Patient Benefits. <i>Clinical Infectious Diseases</i> , 2021, 72, 1975-1978.	2.9	2
317	Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 13-23.	0.4	37
318	RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. <i>Journal of Medical Virology</i> , 2021, 93, 300-310.	2.5	82
319	Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 72, 1256-1258.	2.9	56
320	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. <i>Clinical Infectious Diseases</i> , 2021, 72, 1067-1073.	2.9	4
321	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. <i>Vascular</i> , 2021, 29, 220-227.	0.4	1
322	Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 62-75.	1.0	13
323	Research in the Context of a Pandemic. <i>New England Journal of Medicine</i> , 2021, 384, 755-757.	13.9	50
324	Remdesivir and its antiviral activity against COVID-19: A systematic review. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 123-127.	0.9	143
325	What will travel medicine look like in the COVID-19 pandemic era?. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	10
326	Does IHU-Mediterranean Infection influence Gilead Sciences' stock price?. <i>New Microbes and New Infections</i> , 2021, 39, 100711.	0.8	2
327	Special Review: The future of Immunotherapy. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	5
328	Off-Target <i>In Vitro</i> Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	38
329	One year update on the COVID-19 pandemic: Where are we now?. <i>Acta Tropica</i> , 2021, 214, 105778.	0.9	142
330	Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. <i>Biomedical Journal</i> , 2021, 44, 7-17.	1.4	38
331	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 95-103.	1.3	46
332	Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19. <i>Journal of Controlled Release</i> , 2021, 329, 87-95.	4.8	21
333	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , 2021, 41, 1375-1426.	5.0	28

#	ARTICLE	IF	CITATIONS
334	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. <i>Annals of Internal Medicine</i> , 2021, 174, 93-95.	2.0	38
335	Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope. <i>International Immunopharmacology</i> , 2021, 90, 107156.	1.7	5
336	An effective drug against COVID-19: reality or dream?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 505-518.	1.0	11
337	Synthesis of potentially new schiff bases of N-substituted-2-quinolonylacetohydrazides as anti-COVID-19 agents. <i>Journal of Molecular Structure</i> , 2021, 1230, 129649.	1.8	19
338	Management of Pregnancy during the COVID-19 Pandemic. <i>Global Challenges</i> , 2021, 5, 2000052.	1.8	11
339	Remdesivir for Adults With COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 209-220.	2.0	59
340	COVID19- clinical presentation and therapeutic considerations. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 125-131.	1.0	26
341	COVID-19: neonatal/perinatal perspectives. <i>Journal of Perinatology</i> , 2021, 41, 940-951.	0.9	62
342	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13
343	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. <i>Frontiers in Molecular Biosciences</i> , 2021, 7, 585899.	1.6	12
344	Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. <i>The Lancet Global Health</i> , 2021, 9, e366-e371.	2.9	92
345	Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2. <i>Computers in Biology and Medicine</i> , 2021, 129, 104156.	3.9	31
346	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	13.9	357
347	Remdesivir: From Ebola to COVID-19. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 145-150.	1.0	39
348	In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease. <i>Frontiers in Chemistry</i> , 2020, 8, 595097.	1.8	28
349	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 89-99.	1.3	21
350	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 238-251.	13.9	1,483
351	Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. <i>Drug Research</i> , 2021, 71, 138-148.	0.7	10

#	ARTICLE	IF	CITATIONS
352	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2170-2185.	1.1	15
353	COVID-19 in pregnancy and the puerperium: A review for emergency physicians. <i>American Journal of Emergency Medicine</i> , 2021, 40, 193-198.	0.7	33
354	Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. <i>Journal of Neurology</i> , 2021, 268, 1580-1591.	1.8	34
355	Pregnancy and COVID-19: pharmacologic considerations. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 195-203.	0.9	57
356	Review of Ebola virus disease in children – how far have we come?. <i>Paediatrics and International Child Health</i> , 2021, 41, 12-27.	0.3	5
357	Drugs, host proteins and viral proteins: how their promiscuities shape antiviral design. <i>Biological Reviews</i> , 2021, 96, 205-222.	4.7	7
358	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 34-48.	0.6	85
359	Lines of Treatment of COVID-19 Infection. , 2021, , 91-144.		1
360	Targeting Molecular and Cellular Mechanisms in SARS-CoV-2 Novel Coronavirus Disease 2019 (COVID-19). , 2021, , 517-536.		0
361	Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 47-53.	1.0	3
362	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-12.	26.7	37
363	COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. <i>Molecular Diversity</i> , 2022, 26, 629-645.	2.1	15
364	Therapeutic targets and potential agents for the treatment of COVID-19. <i>Medicinal Research Reviews</i> , 2021, 41, 1775-1797.	5.0	21
365	Therapeutic options for COVID-19: a quick review. <i>Journal of Chemotherapy</i> , 2021, 33, 67-84.	0.7	10
366	Antibodies to watch in 2021. <i>MAbs</i> , 2021, 13, 1860476.	2.6	237
367	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. <i>MAbs</i> , 2021, 13, 1930636.	2.6	13
368	Drug Combinations. , 2021, , .		0
369	Pharmacologic Treatment of COVID-19: Evidence-Based Update. <i>Indian Journal of Respiratory Care</i> , 2021, 10, S34-S38.	0.1	3

#	ARTICLE	IF	CITATIONS
370	COVID-19: can we treat the mother without harming her baby?. Journal of Developmental Origins of Health and Disease, 2021, , 1-11.	0.7	4
371	A review on potential of natural products in the management of COVID-19. RSC Advances, 2021, 11, 16711-16735.	1.7	59
372	Nanotechnology Enabled Solutions to Combat Covid-19: Prevention, Treatment, and Diagnosis. Current Pharmaceutical Biotechnology, 2022, 23, 98-111.	0.9	2
373	COVID-19: An overview and a clinical update. World Journal of Clinical Cases, 2021, 9, 8-23.	0.3	38
374	A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment. Journal of Evidence-based Integrative Medicine, 2021, 26, 2515690X2110037.	1.4	2
375	COVID-19: treatments and the potential for cardiotoxicity. British Journal of Cardiology, 2021, , .	0.7	3
376	Acute treatment with monoclonal antibodies: their design and their use. Microbiology Australia, 2021, 42, 39.	0.1	0
377	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Alexander Saltanov Intensive Care Herald, 2021, , 9-143.	0.2	6
378	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
379	Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop. MBio, 2021, 12, .	1.8	10
380	Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. MAbs, 2021, 13, 1953683.	2.6	20
381	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses, 2021, 13, 134.	1.5	56
382	Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2020, 7, 606429.	1.2	45
383	An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells. PLoS ONE, 2021, 16, e0245024.	1.1	4
384	Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus. Journal of Infectious Diseases, 2021, , .	1.9	7
385	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
386	Ocular manifestations of emerging viral diseases. Eye, 2021, 35, 1117-1139.	1.1	26
387	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection, 2021, 49, 401-410.	2.3	66

#	ARTICLE	IF	CITATIONS
388	Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. <i>Indian Journal of Anaesthesia</i> , 2021, 65, 41.	0.3	51
389	Use of Immunoglobulins in the Prevention of Viral Infections. , 2021, , 267-280.		1
390	Development of a Well-Characterized Rhesus Macaque Model of Ebola Virus Disease for Support of Product Development. <i>Microorganisms</i> , 2021, 9, 489.	1.6	10
391	Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. <i>Frontiers in Immunology</i> , 2021, 12, 632890.	2.2	53
392	Microvascular Angiopathic Consequences of COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 636843.	1.1	25
393	Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. <i>3 Biotech</i> , 2021, 11, 110.	1.1	2
395	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. <i>Antiviral Research</i> , 2021, 186, 105011.	1.9	15
396	Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013â€16 West Africa epidemic. <i>Nature Communications</i> , 2021, 12, 1153.	5.8	10
398	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Contemporary Clinical Trials</i> , 2021, 101, 106272.	0.8	64
399	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	2.2	20
400	Thrombocytopenia in Virus Infections. <i>Journal of Clinical Medicine</i> , 2021, 10, 877.	1.0	60
401	Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 585331.	1.6	10
402	Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. <i>BMC Nephrology</i> , 2021, 22, 52.	0.8	34
403	Ethics of emerging infectious disease outbreak responses: Using Ebola virus disease as a case study of limited resource allocation. <i>PLoS ONE</i> , 2021, 16, e0246320.	1.1	5
404	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. <i>PLoS Pathogens</i> , 2021, 17, e1009312.	2.1	16
405	A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 590154.	1.6	8
406	Prevalence of Foreign Body Aspiration in Children in a Tertiary Care Hospital. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 111-115.	0.1	3
409	Institutional policies and readiness in management of critical illness among patients with viral hemorrhagic fever. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1-6.	1.0	3

#	ARTICLE	IF	CITATIONS
410	Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (<i>S</i>)-P-Phosphoramidation. <i>Journal of Organic Chemistry</i> , 2021, 86, 4977-4985.	1.7	16
411	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. <i>Frontiers in Immunology</i> , 2020, 11, 599568.	2.2	16
412	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <i>Current Pharmaceutical Design</i> , 2021, 27, 115-126.	0.9	13
413	On Topological Indices of Remdesivir Compound Used in Treatment of Corona Virus (COVID 19). <i>Polycyclic Aromatic Compounds</i> , 2022, 42, 4300-4316.	1.4	25
414	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. <i>Frontiers in Medicine</i> , 2021, 8, 606755.	1.2	4
415	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. <i>Microorganisms</i> , 2021, 9, 566.	1.6	13
416	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. <i>Journal of Virology</i> , 2021, 95, .	1.5	6
417	Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. <i>Analytical Biochemistry</i> , 2021, 617, 114118.	1.1	27
418	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 172, 524-541.	3.6	123
420	Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1297-1307.	0.8	4
421	Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. <i>Immunity</i> , 2021, 54, 412-436.	6.6	23
422	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	2.9	24
423	Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. <i>Nature Medicine</i> , 2021, 27, 401-410.	15.2	127
424	Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009300.	1.3	6
425	Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. <i>Human Gene Therapy</i> , 2021, 32, 310-315.	1.4	23
426	Impact of Cardiovascular Diseases on COVID-19: A Systematic Review. <i>Medical Science Monitor</i> , 2021, 27, e930032.	0.5	4
427	Targeting Ebola virus replication through pharmaceutical intervention. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 201-226.	1.9	11
428	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e213071.	2.8	113

#	ARTICLE	IF	CITATIONS
429	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 325-337.	2.4	84
430	Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 5970-5977.	0.7	11
432	Covid19 Drug Efficacy Statistical Analysis. <i>Journal of Physics: Conference Series</i> , 2021, 1827, 012172.	0.3	0
433	Genomic Variation and Treatment Strategies of COVID-19: A Descriptive Review. <i>The Open Covid Journal</i> , 2021, 1, 6-19.	0.4	0
434	Antivirals with common targets against highly pathogenic viruses. <i>Cell</i> , 2021, 184, 1604-1620.	13.5	78
435	Commentary title: COVID-19 research, Africa, and global health. <i>Journal of Virus Eradication</i> , 2021, 7, 100030.	0.3	1
436	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 79-86.	3.0	9
437	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. <i>Nature Communications</i> , 2021, 12, 1577.	5.8	73
438	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential Mechanisms. <i>ACS Omega</i> , 2021, 6, 7454-7468.	1.6	56
439	Combination therapy protects macaques against advanced Marburg virus disease. <i>Nature Communications</i> , 2021, 12, 1891.	5.8	37
440	Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses. <i>Viruses</i> , 2021, 13, 391.	1.5	4
441	Remdesivir: An Antiviral Still Seeking a Raison d'Être. <i>Clinical Infectious Diseases</i> , 2021, 73, 1857-1859.	2.9	0
442	Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development. <i>Lancet, The</i> , 2021, 397, 1229-1236.	6.3	54
443	The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2021, 26, 220-239.	0.3	6
444	Ansumimab: First Approval. <i>Drugs</i> , 2021, 81, 595-598.	4.9	29
445	Epitope Mapping of Exposed Tegument and Alimentary Tract Proteins Identifies Putative Antigenic Targets of the Attenuated Schistosoma Vaccine. <i>Frontiers in Immunology</i> , 2020, 11, 624613.	2.2	13
446	Clinical Pharmacologyâ€Informed Development of COVIDâ€19 Therapeutics: Regulatory Experience. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 810-812.	2.3	2
447	IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008403.	1.3	19

#	ARTICLE	IF	CITATIONS
448	Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. <i>Cells</i> , 2021, 10, 1052.	1.8	26
449	Prodrugs of a 1- β -D-C-4-Aza-7,9-dideazaadenosine <i>C</i> -Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5001-5017.	2.9	40
450	Neutralizing monoclonal antibodies for treatment of COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 382-393.	10.6	568
451	Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. <i>Clinical Epidemiology and Global Health</i> , 2021, 10, 100694.	0.9	78
452	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
453	Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections. <i>Frontiers of Medicine</i> , 2021, 15, 644-648.	1.5	0
454	Neutralizing Antibody Therapeutics for COVID-19. <i>Viruses</i> , 2021, 13, 628.	1.5	99
456	The Involvement of MicroRNAs in SARS-CoV-2 Infection Comorbid with HIV-Associated Preeclampsia. <i>Current Hypertension Reports</i> , 2021, 23, 20.	1.5	9
457	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. <i>Journal of Clinical Medicine</i> , 2021, 10, 1583.	1.0	21
458	Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. <i>Viruses</i> , 2021, 13, 774.	1.5	9
459	Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk. <i>Journal of Reproductive Immunology</i> , 2021, 144, 103271.	0.8	15
460	Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1240-1247.	13.9	57
461	Remdesivir for the treatment of COVID-19 in pregnancy. <i>Journal of Medical Virology</i> , 2021, 93, 4114-4119.	2.5	8
462	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 839-852.	1.4	7
463	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021, 40, 36-49.	0.8	8
464	Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. <i>Cell Reports</i> , 2021, 35, 108984.	2.9	22
465	Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2. <i>Communications Biology</i> , 2021, 4, 500.	2.0	12
466	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. <i>Journal of Environmental and Public Health</i> , 2021, 2021, 1-11.	0.4	24

#	ARTICLE	IF	CITATIONS
467	SARS-CoV-2 spike therapeutic antibodies in the age of variants. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	11
468	A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 8062.	1.6	5
469	Homology Modeling of Coronavirus Structural Proteins and Molecular Docking of Potential Drug Candidates for the Treatment of COVID-19. <i>Coronaviruses</i> , 2021, 2, 241-250.	0.2	1
470	Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	22
471	Current COVID-19 treatments: Rapid review of the literature. <i>Journal of Global Health</i> , 2021, 11, 10003.	1.2	26
472	Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 426-434.	3.6	33
473	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. <i>MBio</i> , 2021, 12, .	1.8	62
474	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. <i>Pharmaceuticals</i> , 2021, 14, 332.	1.7	21
475	Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1970-1972.e3.	2.4	11
476	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of Tj ETQq1 1 0.784314 rgBT /Overlook 2021, 42, 5-18.	0.2	2
477	Use of Remdesivir in Myasthenia gravis and COVID-19. <i>Pharmacotherapy</i> , 2021, 41, 546-550.	1.2	5
478	Monoclonal Antibody Approved to Treat Ebola. <i>American Journal of Nursing</i> , 2021, 121, 22-22.	0.2	4
479	The Ferret as a Model for Filovirus Pathogenesis and Countermeasure Evaluation. <i>ILAR Journal</i> , 2020, 61, 62-71.	1.8	14
480	SARS-CoV-2 prevalence and maternal-perinatal outcomes among pregnant women admitted for delivery: Experience from COVID-19-dedicated maternity hospital in Jammu, Jammu and Kashmir (India). <i>Journal of Medical Virology</i> , 2021, 93, 5505-5514.	2.5	31
481	Therapeutic approaches to coronavirus infection according to "One Health" concept. <i>Research in Veterinary Science</i> , 2021, 136, 81-88.	0.9	1
482	Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. <i>Nano Express</i> , 2021, 2, 022007.	1.2	6
483	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4861-4867.	1.1	7
484	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. <i>Frontiers in Pharmacology</i> , 2021, 12, 660710.	1.6	15

#	ARTICLE	IF	CITATIONS
485	Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1001-1005.	0.8	1
486	Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22795.	1.4	8
487	Major Update: Remdesivir for Adults With COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 663-672.	2.0	71
488	Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. <i>Clinical Microbiology and Infection</i> , 2021, 27, 791.e5-791.e8.	2.8	83
489	Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak. <i>BMC Medical Research Methodology</i> , 2021, 21, 98.	1.4	0
490	Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells. <i>Frontiers in Pharmacology</i> , 2021, 12, 647280.	1.6	2
491	Coronavirus Disease 2019 in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 668484.	0.9	56
492	Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1123-1143.	1.1	8
493	An extended fuzzy decision-making framework using hesitant fuzzy sets for the drug selection to treat the mild symptoms of Coronavirus Disease 2019 (COVID-19). <i>Applied Soft Computing Journal</i> , 2021, 103, 107155.	4.1	71
494	An overview of ProTide technology and its implications to drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1149-1161.	2.5	22
495	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1171, 122641.	1.2	16
496	A 33-year-old man with COVID-19 presented with subacute thyroiditis: A rare case report and literature review. <i>New Microbes and New Infections</i> , 2021, 41, 100871.	0.8	18
497	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <i>Antioxidants</i> , 2021, 10, 881.	2.2	20
498	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. <i>Nutrients</i> , 2021, 13, 1550.	1.7	26
499	Liver and kidney function in patients with Covid-19 treated with remdesivir. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4450-4454.	1.1	29
500	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
501	Quantum mechanical studies of the adsorption of Remdesivir, as an effective drug for treatment of COVID-19, on the surface of pristine, COOH-functionalized and S-, Si- and Al-doped carbon nanotubes. <i>Physica E: Low-Dimensional Systems and Nanostructures</i> , 2021, 129, 114668.	1.3	13
502	Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections. <i>Journal of Infection and Public Health</i> , 2021, 14, 655-660.	1.9	12

#	ARTICLE	IF	CITATIONS
503	Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. <i>Infectious Diseases</i> , 2021, 53, 691-699.	1.4	24
504	Current Overviews on COVID-19 Management Strategies. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	0.9	9
505	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 0, , .	1.5	2
506	Drug combination therapy for emerging viral diseases. <i>Drug Discovery Today</i> , 2021, 26, 2367-2376.	3.2	65
507	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3398-3407.	1.1	1
508	Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	4
509	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. <i>Cell</i> , 2021, 184, 3486-3501.e21.	13.5	39
510	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
511	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	5.8	48
512	Anti-Cancer Potential of Some Commonly Used Drugs. <i>Current Pharmaceutical Design</i> , 2021, 27, 4530-4538.	0.9	9
513	Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. <i>Current Drug Research Reviews</i> , 2021, 13, 184-202.	0.7	3
516	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. <i>PLoS ONE</i> , 2021, 16, e0253487.	1.1	76
517	Antibody responses to filovirus infections in humans: protective or not?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e348-e355.	4.6	3
518	Confronting COVID-19: Current Issues of SARS-CoV-2 Therapeutic Drug/Vaccine Development. <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2021, 26, 91-97.	0.0	0
519	Ebola Outbreak amid COVID-19 in the Republic of Guinea: Priorities for Achieving Control. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1966-1969.	0.6	21
520	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. <i>Frontiers in Pharmacology</i> , 2021, 12, 659577.	1.6	31
521	Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options. <i>Coronaviruses</i> , 2021, 2, 481-491.	0.2	17
522	COVID-19 Treatment Agents: Do They Pose an Environmental Risk?. <i>ACS ES&T Water</i> , 2021, 1, 1555-1565.	2.3	8

#	ARTICLE	IF	CITATIONS
523	Possíveis tratamentos farmacológicos em fase de estudos para pacientes sintomáticos de COVID-19: Uma revisão integrativa. Research, Society and Development, 2021, 10, e37910615579.	0.0	0
524	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. Frontiers in Cellular and Infection Microbiology, 2021, 11, 676451.	1.8	21
525	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells, 2021, 10, 1412.	1.8	6
526	COVID-19 and pregnant women – An overview on diagnosis, treatment approach with limitation, and clinical management. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	1
528	Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open, 2021, 11, e048416.	0.8	46
529	Reflections on 40 Years of AIDS. Emerging Infectious Diseases, 2021, 27, 1553-1560.	2.0	49
530	An update on emerging therapeutics to combat COVID-19. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 104-129.	1.2	9
531	Tackling COVID-19 with neutralizing monoclonal antibodies. Cell, 2021, 184, 3086-3108.	13.5	309
532	The impact of COVID-19 on pregnancy and therapeutic drug development. British Journal of Pharmacology, 2022, 179, 2108-2120.	2.7	11
533	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Review of Anti-Infective Therapy, 2022, 20, 211-229.	2.0	10
534	SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews, 2021, 34, e0010921.	5.7	64
535	Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises. Drug Discovery Today, 2021, 26, 2608-2618.	3.2	2
536	Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis. Human Vaccines and Immunotherapeutics, 2021, 17, 3771-3783.	1.4	3
537	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomedicine and Pharmacotherapy, 2021, 139, 111642.	2.5	50
538	Safety profile of treatments administered in COVID 19 infection in pregnant women. Clinica E Investigacion En Ginecologia Y Obstetricia, 2021, 48, 100663.	0.1	4
539	Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease. PLoS ONE, 2021, 16, e0252874.	1.1	11
540	The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. Life, 2021, 11, 734.	1.1	34
541	Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 697876.	1.8	40

#	ARTICLE	IF	CITATIONS
542	The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic. <i>Pharmaceutical Medicine</i> , 2021, 35, 203-213.	1.0	11
543	SARS-CoV-2: Origin, Pathogenesis and Therapeutic Interventions. <i>Coronaviruses</i> , 2021, 2, .	0.2	2
544	Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an <i>in silico</i> perspective. <i>Future Virology</i> , 2021, 16, 467-474.	0.9	8
545	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1219-1244.	2.0	6
546	Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone. <i>PLoS ONE</i> , 2021, 16, e0252905.	1.1	5
547	Pharmacological Treatment for the Management of COVID 19: A Narrative Review. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 614-621.	0.1	3
548	Contemporary narrative review of treatment options for COVID 19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
549	Global health security as it pertains to Zika, Ebola, and COVID-19. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 401-408.	1.3	5
550	Antimicrobial immunotherapeutics: past, present and future. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 609-628.	1.1	1
551	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	1.5	33
552	Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	6
553	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now "New Hopes?". <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3
554	Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 690976.	2.2	4
555	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. <i>Cell Reports</i> , 2021, 36, 109433.	2.9	75
556	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. <i>Biochemical Journal</i> , 2021, 478, 2405-2423.	1.7	46
558	SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies—a narrative review. <i>Journal of Infection and Public Health</i> , 2021, 14, 863-875.	1.9	43
559	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 699949.	1.6	15
560	An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). <i>Expert Opinion on Drug Discovery</i> , 2021, , 1-10.	2.5	16

#	ARTICLE	IF	CITATIONS
561	Bio-safety and bio-security: A major global concern for ongoing COVID-19 pandemic. Saudi Journal of Biological Sciences, 2022, 29, 132-139.	1.8	5
562	Remdesivir for the treatment of COVID-19. The Cochrane Library, 2021, 2021, CD014962.	1.5	90
563	Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches. Molecular Biology Reports, 2021, 48, 6513-6524.	1.0	6
565	Remdesivir inhibits the polymerases of the novel filoviruses Lloviu and Bombali virus. Antiviral Research, 2021, 192, 105120.	1.9	8
566	Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice. Frontiers in Pharmacology, 2021, 12, 692346.	1.6	4
567	Remdesivir for the treatment of Covid-19: the value of biochemical studies. Current Opinion in Virology, 2021, 49, 81-85.	2.6	17
568	Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 88-90.	0.2	4
569	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications. Journal of Heterocyclic Chemistry, 2021, 58, 2226-2260.	1.4	15
570	Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. Journal of Innate Immunity, 2022, 14, 135-147.	1.8	1
571	Plant-made vaccines and therapeutics. Science, 2021, 373, 740-741.	6.0	27
572	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. BioScience Trends, 2021, 15, 205-210.	1.1	8
573	Interactions Between Specific Immune Status of Pregnant Women and SARS-CoV-2 Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 721309.	1.8	7
574	A review of remdesivir for COVID-19 in pregnancy and lactation. Journal of Antimicrobial Chemotherapy, 2021, 77, 24-30.	1.3	22
575	What is the role of remdesivir in patients with COVID-19?. Current Opinion in Critical Care, 2021, 27, 487-492.	1.6	16
576	Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness. Expert Opinion on Drug Safety, 2021, 20, 1299-1307.	1.0	11
577	Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias. Revista Bionatura, 2021, 3, 2091-2113.	0.1	0
578	Topological Study of Line Graph of Remdesivir Compound Used in the Treatment of Corona Virus. Polycyclic Aromatic Compounds, 0, , 1-17.	1.4	8
579	Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Frontiers in Immunology, 2021, 12, 721328.	2.2	28

#	ARTICLE	IF	CITATIONS
580	Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	124
581	The Methanolic Extract of <i>Perilla frutescens</i> Robustly Restricts Ebola Virus Glycoprotein-Mediated Entry. <i>Viruses</i> , 2021, 13, 1793.	1.5	6
582	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3237-3248.	2.0	4
583	Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. <i>Vaccines</i> , 2021, 9, 992.	2.1	53
584	Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0111721.	1.4	22
585	Human plasma IgG1 repertoires are simple, unique, and dynamic. <i>Cell Systems</i> , 2021, 12, 1131-1143.e5.	2.9	37
586	Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. <i>Pathogens</i> , 2021, 10, 1201.	1.2	9
588	Antibody therapy for COVID-19. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 553-558.	1.1	17
589	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. <i>Scientific Reports</i> , 2021, 11, 19458.	1.6	9
590	Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. <i>Molecular Pharmacology</i> , 2021, 100, 548-557.	1.0	32
591	Ebola Virus Disease, Diagnostics and Therapeutics: Where is the Consensus in Over Three Decades of Clinical Research?. <i>Scientific African</i> , 2021, 13, e00862.	0.7	1
592	Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program. <i>International Journal of Infectious Diseases</i> , 2021, 113, 166-167.	1.5	9
593	Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice. <i>Vaccines</i> , 2021, 9, 978.	2.1	20
594	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. <i>Animal Diseases</i> , 2021, 1, 15.	0.6	4
595	SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0026121.	1.2	47
596	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3
597	Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 955.	1.7	12
598	The Cardiac Effects of COVID-19: Review of articles. <i>Current Problems in Cardiology</i> , 2022, 47, 100981.	1.1	3

#	ARTICLE	IF	CITATIONS
599	Construction and evaluation of DNA vaccine encoding Ebola virus glycoprotein fused with lysosome-associated membrane protein. <i>Antiviral Research</i> , 2021, 193, 105141.	1.9	4
600	Recent advances in combating Nipah virus. <i>Faculty Reviews</i> , 2021, 10, 74.	1.7	15
601	Therapeutics development for Ebola virus disease: A recent scenario. <i>Current Opinion in Pharmacology</i> , 2021, 60, 208-215.	1.7	12
602	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113654.	2.6	10
603	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. <i>Pharmacological Research</i> , 2021, 173, 105848.	3.1	16
604	Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113862.	2.6	8
605	Drug repurposing for COVID-19: Approaches, challenges and promising candidates. , 2021, 228, 107930.		85
606	Drugs for the Treatment of COVID-19. , 2021, , 193-204.		0
607	Remdesivir â€œ Current evidence & perspective in management of COVID-19 infection. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1808.	0.3	5
608	Emerging Potential of Metallodrugs to Target Coronavirus: Efficacy, Toxicity and their Mechanism of Action. <i>Asian Journal of Chemistry</i> , 2021, 33, 1191-1207.	0.1	1
609	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. <i>Membranes</i> , 2021, 11, 64.	1.4	0
610	Normalizing images is good to improve computer-assisted COVID-19 diagnosis. , 2021, , 51-62.		4
611	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 955.	1.2	6
612	Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review. <i>Hypertension Research</i> , 2021, 44, 386-398.	1.5	14
613	Aspects of epidemiology, pathology, virology, immunology, transmission, prevention, prognosis, diagnosis, and treatment of COVID-19 Pandemic: A narrative review. <i>International Journal of Preventive Medicine</i> , 2021, 12, 38.	0.2	7
614	REGN-EB3: First Approval. <i>Drugs</i> , 2021, 81, 175-178.	4.9	69
615	Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. <i>Current Opinion in Pediatrics</i> , 2021, Publish Ahead of Print, 129-135.	1.0	3
616	Pharmacotherapeutics of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 12-37.	2.1	4

#	ARTICLE	IF	CITATIONS
617	COVID-19 Antiviral and Treatment Candidates: Current Status. <i>Immune Network</i> , 2021, 21, e7.	1.6	8
618	The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110425.	1.0	17
619	Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 3-22.	0.8	5
620	Monoclonal Antibody. , 2021, , .		0
621	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <i>Infection and Chemotherapy</i> , 2021, 53, 166.	1.0	21
622	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
623	Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports. <i>IDCases</i> , 2021, 26, e01254.	0.4	9
624	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.	3.0	16
625	Progresses in clinical studies on antiviral therapies for COVID-19: Experience and lessons in design of clinical trials. <i>Pediatric Investigation</i> , 2020, 4, 263-274.	0.6	7
626	Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 659-671.	1.2	197
627	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	1.4	22
628	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 641-648.	1.8	142
629	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. , 0, .		1
630	SARS-CoV-2 and Pregnancy: A Review of the Facts. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2020, 42, 562-568.	0.3	11
631	Intensive Care Unit-Like Care of Nonhuman Primates with Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2021, 224, 632-642.	1.9	3
632	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). <i>Critical Care Medicine</i> , 2020, 48, e440-e469.	0.4	816
633	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 359-367.	0.8	53
634	Cardiovascular implications and complications of the coronavirus disease-2019 pandemic: a world upside down. <i>Current Opinion in Cardiology</i> , 2021, 36, 241-251.	0.8	5

#	ARTICLE	IF	CITATIONS
635	Combination of Remdesivir, Corticosteroid, and Convalescent Plasma for Severe COVID-19 in Perivable Pregnancy. <i>Infectious Diseases in Clinical Practice</i> , 2020, 28, e21-e23.	0.1	2
660	Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric and Adult Congenital Heart Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e017224.	1.6	80
661	The convalescent sera option for containing COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 1545-1548.	3.9	775
662	Panic prescribing has become omnipresent during the COVID-19 pandemic. <i>Journal of Clinical Investigation</i> , 2020, 130, 2752-2753.	3.9	8
663	Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. <i>Trials</i> , 2020, 21, 422.	0.7	59
664	Therapeutic strategies for critically ill patients with COVID-19. <i>Annals of Intensive Care</i> , 2020, 10, 45.	2.2	100
665	Battling COVID-19: using old weapons for a new enemy. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2020, 6, 6.	0.9	20
666	Leveraging investments in Ebola preparedness for COVID-19 in Sub-Saharan Africa. <i>AAS Open Research</i> , 2020, 3, 3.	1.5	9
667	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 2020, 9, 1109.	0.8	8
668	Novel respiratory infectious diseases in Korea. <i>Yeungnam University Journal of Medicine</i> , 2020, 37, 286-295.	0.7	4
669	Wuhan 2019 Novel Coronavirus - 2019-nCoV. <i>Materials and Methods</i> , 0, 10, .	0.0	65
670	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 463-471.	0.6	5
671	Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. <i>Cmaj</i> , 2020, 192, E745-E755.	0.9	78
673	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. <i>Discoveries</i> , 2020, 8, e121.	1.5	15
674	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e13105.	3.3	62
675	Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. <i>EMBO Molecular Medicine</i> , 2021, 13, e13426.	3.3	87
676	Pregnancy and Coronavirus Disease 19. <i>Integrative Journal of Medical Sciences</i> , 0, 7, .	0.0	1
678	Ebola Virus Disease Outbreak â€” Democratic Republic of the Congo, August 2018â€”November 2019. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 1162-1165.	9.0	69

#	ARTICLE	IF	CITATIONS
679	Diagnosis and treatment of acute coronary syndrome during the novel coronavirus infection COVID-19 pandemic. Russian Journal of Cardiology, 2020, 25, 3854.	0.4	6
680	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Memorias Do Instituto Oswaldo Cruz, 2020, 115, e200254.	0.8	26
681	Use of remdesivir for patients with Covid-19: a review article. Revista Da Associação Médica Brasileira, 2020, 66, 838-841.	0.3	6
682	The COVID-19 Pandemic - A Global Public Health Crisis: A Brief Overview Regarding Pharmacological Interventions. Pesquisa Brasileira Em Odontopediatria E Clínica Integrada, 2020, 20, .	0.7	9
684	Coronavirus disease: a global problem of the 21st century. Complex Issues of Cardiovascular Diseases, 2020, 9, 6-16.	0.3	12
686	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Alexander Saltanov Intensive Care Herald, 2020, , 9-120.	0.2	11
687	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. SSRN Electronic Journal, 0, , .	0.4	15
688	In Vitro Data of Current Therapies for SARS-CoV-2. Current Medicinal Chemistry, 2020, 27, 4542-4548.	1.2	17
689	Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. Current Topics in Medicinal Chemistry, 2020, 20, 2210-2220.	1.0	16
690	Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. Current Topics in Medicinal Chemistry, 2020, 20, 1423-1433.	1.0	36
691	COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Pharmaceutical Nanotechnology, 2020, 8, 323-353.	0.6	13
692	The landscape of COVID-19 clinical trials in Latin America and the Caribbean: assessment and challenges. Revista Panamericana De Salud Pública/Pan American Journal of Public Health, 2020, 44, 1.	0.6	10
693	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century. Iranian South Medical Journal, 2020, 22, 432-450.	0.2	64
694	COVID-19 Treatment: The Race Against Time. Electronic Journal of General Medicine, 2020, 17, em227.	0.3	17
695	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. Electronic Journal of General Medicine, 2020, 17, em251.	0.3	12
696	Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice. Acta Hepatologica Japonica, 2020, 61, 496-503.	0.0	2
697	Medication for COVID-19 – an Overview of Approaches Currently Under Study. Deutsches Ärztblatt International, 2020, 117, 213-219.	0.6	31
698	Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. Frontiers in Immunology, 2020, 11, 605170.	2.2	101

#	ARTICLE	IF	CITATIONS
699	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
700	A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures. <i>Viruses</i> , 2021, 13, 52.	1.5	14
701	Plant-Based Drugs and Vaccines for COVID-19. <i>Vaccines</i> , 2021, 9, 15.	2.1	34
702	Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	6
704	Coronavirus disease 2019 (COVID-19): research progress and clinical practice. <i>Global Health & Medicine</i> , 2020, 2, 78-88.	0.6	16
705	O Efeito da Doenasa de Coronavarus 2019 nas Doenas Cardiovasculares. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 114, 817-822.	0.3	29
706	Confronting the threat of SARSCoV2: Realities, challenges and therapeutic strategies (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 155.	0.8	6
707	Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review). <i>International Journal of Molecular Medicine</i> , 2020, 46, 467-488.	1.8	116
708	An integrative look at SARSCoV2 (Review). <i>International Journal of Molecular Medicine</i> , 2020, 47, 415-434.	1.8	17
709	Empirical Treatment and Prevention of COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 142.	1.0	18
710	Interim Guidelines on Antiviral Therapy for COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 281.	1.0	29
711	Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). <i>Journal of Microbiology and Biotechnology</i> , 2020, 30, 313-324.	0.9	709
712	Recommendations for the COVID-19 Response at the National Level Based on Lessons Learned from the Ebola Virus Disease Outbreak in the Democratic Republic of the Congo. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 12-17.	0.6	43
713	Responding to the Challenge of the Dual COVID-19 and Ebola Epidemics in the Democratic Republic of CongoPriorities for Achieving Control. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 597-602.	0.6	39
714	A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. <i>European Journal of Rheumatology</i> , 2020, 7, S102-S106.	1.3	1
715	COVID-19 compared to other epidemic coronavirus diseases and the flu. <i>World Journal of Clinical Infectious Diseases</i> , 2020, 10, 1-13.	0.5	8
716	An evidence-based framework for priority clinical research questions for COVID-19. <i>Journal of Global Health</i> , 2020, 10, .	1.2	22
717	The journey of remdesivir: from Ebola to COVID-19. <i>Drugs in Context</i> , 2020, 9, 1-9.	1.0	106

#	ARTICLE	IF	CITATIONS
718	Cardiac Adverse Events With Remdesivir in COVID-19 Infection. <i>Cureus</i> , 2020, 12, e11132.	0.2	58
719	Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. <i>Cureus</i> , 2020, 12, e8342.	0.2	30
720	Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. <i>The Enzymes</i> , 2021, 49, 315-354.	0.7	9
721	CoV-er all the bases: Structural perspectives of SARS-CoV-2 RNA synthesis. <i>The Enzymes</i> , 2021, 49, 1-37.	0.7	6
722	Viral Load in Non-Surviving Liberian Ebola Virus Disease Patients Is Underestimated by Diagnostic qRT-PCR: A Retrospective Observational Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
723	The Role of Animal Research in Pandemic Responses. <i>Comparative Medicine</i> , 2021, 71, 359-368.	0.4	2
724	Genomics serology to inform therapies and vaccines for arthritogenic alphaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	0
725	A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. <i>Saudi Journal of Biological Sciences</i> , 2021, 29, 860-860.	1.8	5
726	Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review. <i>Cardiovascular Toxicology</i> , 2022, 22, 268-272.	1.1	39
727	The use of antiviral drugs in children. <i>Journal of Chemotherapy</i> , 2022, 34, 73-86.	0.7	0
729	An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher. <i>American Journal of Public Health</i> , 2021, 111, e1-e4.	1.5	0
730	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4328-4344.	1.4	13
731	COVID-19, children, clinical trials and compassion: The ethical case for using innovative or compassionate treatments. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, , .	0.7	4
732	Current treatment strategies for COVID-19 (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	19
734	Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus. <i>Virologica Sinica</i> , 2021, 36, 1600-1610.	1.2	5
735	Remdesivir triphosphate blocks DNA synthesis and increases exonucleolysis by the replicative mitochondrial DNA polymerase, Pol γ . <i>Mitochondrion</i> , 2021, 61, 147-158.	1.6	5
737	A literature review of drugs for the treatment of COVID-19. <i>Caribbean Medical Journal</i> , 0, , .	0.1	0
738	A REVIEW ON CORONAVIRUS DISEASE 2019. <i>British Journal of Medical and Health Research</i> , 2020, 7, 40-50.	0.1	0

#	ARTICLE	IF	CITATIONS
740	When Shall Coronavirus Disease-19 Stop? Review of Literature. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 75-81.	0.1	1
741	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. Russian Journal of Infection and Immunity, 2020, 10, 277-286.	0.2	2
743	Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 159-161.	0.2	1
745	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. Drug Discoveries and Therapeutics, 2020, 14, 109-116.	0.6	4
746	Going back in time for an antibody to fight COVID-19. Nature, 2020, 583, 203-204.	13.7	1
747	Perspectives on COVID-19 therapies: conflicts and consensus. Research, Society and Development, 2020, 9, e85997019.	0.0	1
748	Antiviral treatment for COVID-19: the evidence supporting remdesivir. Clinical Medicine, 2020, 20, e215-e217.	0.8	4
749	Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell, 2021, 184, 5593-5607.e18.	13.5	21
750	Telehealth and Pharmacological Strategies of COVID-19 Prevention: Current and Future Developments. Studies in Systems, Decision and Control, 2022, , 897-927.	0.8	0
752	Impact of COVID-19 on Delivery of Chemotherapy in Hospitals in Spain and France. SSRN Electronic Journal, 0, , .	0.4	0
753	COVID-19 Treatment at a Glance. Turkish Thoracic Journal, 2020, 21, 438-445.	0.2	2
754	On the molecular structure of Remdesivir for the treatment of Covid-19. Computer Methods in Biomechanics and Biomedical Engineering, 2021, 24, 995-1002.	0.9	6
755	A Review on Drug Repurposing: A Strategy to Treat Human Coronavirus Disease (COVID-19). International Journal of Tropical Disease & Health, 0, , 42-54.	0.1	0
756	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. Journal of Biomedical Research & Environmental Sciences, 2020, 1, 431-438.	0.1	2
757	The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis. Case Reports in Infectious Diseases, 2020, 2020, 1-5.	0.2	1
758	Clinical Features and Treatment of Coronavirus Disease-19 (Severe Acute Respiratory Syndrome) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.1	1
759	Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center. APIK Journal of Internal Medicine, 2021, 9, 244.	0.1	0
760	Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods in Enzymology, 2021, 660, 239-263.	0.4	5

#	ARTICLE	IF	CITATIONS
761	Viral Infections in Obstetric Critical Care. , 2020, , 231-242.		0
763	Insights into Novel Coronavirus and COVID-19 Outbreak. Medical Virology, 2020, , 1-17.	2.1	5
765	Coronavirus Disease 2019 (COVID-19): review study. Jorjani Biomedicine Journal, 2020, 8, 4-10.	0.1	2
766	COVID 19 opciones terapeuticas desde la viro-patogenesis a la evidencia clinica. Revista Colombiana De NefrologÃa, 2020, 7, 5-6.	0.1	0
768	A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Antiâ€SARSâ€CoVâ€2 Monoclonal Antibodies to Advance Bamlanivimab Into a Firstâ€inâ€Human Clinical Trial. Clinical Pharmacology and Therapeutics, 2022, 111, 595-604.	2.3	14
769	COVID-19 Therapeutics and Vaccines: A Race to Save Lives. Toxicological Sciences, 2022, 185, 119-127.	1.4	8
770	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARSâ€CoVâ€2 Activity. ChemistrySelect, 2021, 6, 11502-11527.	0.7	8
771	Establishing Healthcare Worker Performance and Safety in Providing Critical Care for Patients in a Simulated Ebola Treatment Unit: Non-Randomized Pilot Study. Viruses, 2021, 13, 2205.	1.5	1
772	Identification and Development of Therapeutics for COVID-19. MSystems, 2021, 6, e0023321.	1.7	20
773	Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. Journal of Infection and Public Health, 2022, 15, 116-122.	1.9	20
774	Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Current Opinion in Virology, 2021, 51, 179-189.	2.6	7
776	A Review on Current Scenario of 2019-nCoV and Its Treatments. American Journal of Applied Bio-Technology Research, 2020, 1, 1-15.	0.1	0
777	Ãžocuklarda COVID-19 Tedavisi. Turkish Journal of Pediatric Disease, 0, , 9-14.	0.0	0
778	COVID 19 opciones terapeuticas desde la viro-patogenesis a la evidencia clinica. Revista Colombiana De NefrologÃa, 2020, 7, 17-18.	0.1	0
779	Main Pharmacological Strategies Against SARS-CoV-2. Medicina Moderna, 2020, 27, 153-157.	0.0	0
781	Cracking the cell access code for the deadly virus VEEV. Nature, 2020, 588, 223-224.	13.7	0
785	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. F1000Research, 0, 9, 1109.	0.8	7
786	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12.	26.7	0

#	ARTICLE	IF	CITATIONS
787	An evidence-based framework for priority clinical research questions for COVID-19. <i>Journal of Global Health</i> , 2020, 10, 011001.	1.2	11
788	Therapeutic strategies against COVID-19. <i>Acta Biomedica</i> , 2020, 91, e2020038.	0.2	3
789	Prevention of Emerging Infections in Children. <i>Pediatric Clinics of North America</i> , 2022, 69, 185-202.	0.9	2
790	Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo. <i>Vaccine</i> , 2021, , .	1.7	0
791	Characterizing the inclusion of pregnant and breastfeeding people in infectious diseases randomized controlled trials: a targeted literature review. <i>Clinical Microbiology and Infection</i> , 2021, , .	2.8	4
792	Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital. <i>Cureus</i> , 2021, 13, e19487.	0.2	2
793	Current status of therapeutic approaches and vaccines for SARS-CoV-2. <i>Future Microbiology</i> , 2021, 16, 1319-1326.	1.0	2
794	COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14.	1.9	10
795	Overview of Neutralizing Antibodies and Their Potential in COVID-19. <i>Vaccines</i> , 2021, 9, 1376.	2.1	37
797	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <i>World Journal of Pharmacology</i> , 2021, 10, 1-32.	1.3	1
798	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 778829.	2.2	2
800	Perinatal COVID-19. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e504-e506.	1.1	6
801	Sterile protection against malaria in humans with a monoclonal antibody. <i>Med</i> , 2021, 2, 1198-1200.	2.2	1
802	Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12638.	1.8	45
803	Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic. <i>Antibiotics</i> , 2021, 10, 1477.	1.5	5
805	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
807	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0
808	Recent Advances on Drugs and Vaccines for COVID-19. <i>Inquiry (United States)</i> , 2021, 58, 004695802110556.	0.5	3

#	ARTICLE	IF	CITATIONS
809	Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses. RSC Drug Discovery Series, 2021, , 256-279.	0.2	0
810	Anno 2021: Which antivirals for the coming decade?. Annual Reports in Medicinal Chemistry, 2021, 57, 49-107.	0.5	4
813	Reproducibility and flexibility of monoclonal antibody production with <i>Nicotiana benthamiana</i> . MAbs, 2022, 14, 2013594.	2.6	7
814	Development of plant-made monoclonal antibodies against viral infections. Current Opinion in Virology, 2022, 52, 148-160.	2.6	19
815	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Vicious Circle. , 0, , .		6
816	Epidemiological Assessment and Challenges of the COVID-19 Pandemic in Nigeria. Microbiology Research Journal International, 0, , 11-29.	0.2	0
817	Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agent. Bioinformation, 2020, 16, 878-881.	0.2	1
818	COVID-19 and Pregnancy: Citation Network Analysis and Evidence Synthesis. JMIR Pediatrics and Parenting, 2022, 5, e29189.	0.8	1
819	Combating SARS-CoV-2: Potential Therapeutic Candidates Against COVID-19. European Medical Journal Allergy & Immunology, 0, , 61-70.	0.0	1
820	Plasma therapy: a passive resistance against the deadliest. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	1.4	5
821	COVID-19 AND UPPER LIMB ANOMALIES IN NEWBORNS: A REASON FOR CONCERN?. Acta Ortopedica Brasileira, 2022, 30, e252308.	0.2	1
822	A review of COVID-19 therapeutics in pregnancy and lactation. Obstetric Medicine, 2022, 15, 225-232.	0.5	13
823	Recent advances in molecular farming using monocot plants. Biotechnology Advances, 2022, 58, 107913.	6.0	16
825	Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. Heliyon, 2022, 8, e08835.	1.4	14
826	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences, 2022, 18, 459-472.	2.6	65
827	Discovery of compounds inhibiting SARS-COV-2 multi-targets. Journal of Biomolecular Structure and Dynamics, 2023, 41, 2602-2617.	2.0	3
828	Filoviruses: modern solutions to life-threatening infections. , 2022, , 369-394.		0
829	Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. Emerging Microbes and Infections, 2022, 11, 548-551.	3.0	8

#	ARTICLE	IF	CITATIONS
830	Spike-Dependent Oposonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 808932.	2.2	34
831	Potential Application of Exosomes in Vaccine Development and Delivery. <i>Pharmaceutical Research</i> , 2022, 39, 2635-2671.	1.7	24
832	Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. <i>Frontiers in Immunology</i> , 2021, 12, 808047.	2.2	4
833	Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, 71.	1.3	0
834	Total synthesis of remdesivir. <i>Tetrahedron Letters</i> , 2022, 88, 153590.	0.7	6
835	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. <i>New England Journal of Medicine</i> , 2022, 386, 305-315.	13.9	813
836	Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. <i>Journal of Biological Chemistry</i> , 2022, 298, 101529.	1.6	25
837	Human Antibodies for Viral Infections. <i>Annual Review of Immunology</i> , 2022, 40, 349-386.	9.5	23
838	MOLECULAR DOCKING OF GANOMESTENOL WITH SARS-COV-2 MPRO. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 46-47.	0.3	0
839	Inhibition of SARS-Cov-2 proteases by medicinal plant bioactive constituents: Molecular docking simulation. <i>IOP Conference Series: Earth and Environmental Science</i> , 2022, 976, 012054.	0.2	0
840	A Decision-Making Framework Using q-Rung Orthopair Probabilistic Hesitant Fuzzy Rough Aggregation Information for the Drug Selection to Treat COVID-19. <i>Complexity</i> , 2022, 2022, 1-37.	0.9	14
841	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> , The, 2022, 399, 665-676.	6.3	280
843	Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. <i>Science Translational Medicine</i> , 2022, 14, eabi5229.	5.8	22
844	Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. <i>Current Opinion in Virology</i> , 2022, 53, 101204.	2.6	21
845	A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV. <i>Frontiers in Medicine</i> , 2021, 8, 628370.	1.2	35
846	A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. <i>Nature Medicine</i> , 2021, 27, 2224-2233.	15.2	65
849	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	1.7	5
850	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. <i>Antiviral Therapy</i> , 2022, 27, 135965352210827.	0.6	10

#	ARTICLE	IF	CITATIONS
851	Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. <i>Microbiology Spectrum</i> , 2022, 10, e0256021.	1.2	6
852	Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. <i>Journal of Personalized Medicine</i> , 2022, 12, 349.	1.1	3
853	Data and Safety Monitoring Board Monitoring of Clinical Trials for Early Efficacy. , 2022, 1, .		3
854	Efficacy of repurposed antiviral drugs: Lessons from COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 1954-1960.	3.2	24
855	Prodrug Therapies for Infectious and Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2022, 14, 518.	2.0	3
857	T and B Cells Immune Response and the importance of vaccines Against SARS-CoV-2. <i>Revista Bionatura</i> , 2022, 7, 1-8.	0.1	0
858	Remdesivir use in pregnancy during the SARS-CoV-2 pandemic. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 9445-9451.	0.7	8
859	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. <i>Biomedicines</i> , 2022, 10, 437.	1.4	5
860	Anti-influenza Virus Activity of Methylthio-Formycin Distinct From That of T-705. <i>Frontiers in Microbiology</i> , 2022, 13, 802671.	1.5	4
861	What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?. <i>Frontiers in Microbiology</i> , 2022, 13, 843587.	1.5	1
862	Therapeutic strategies for COVID-19 patients: An update. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
863	Nanomedicines Targeting Respiratory Injuries for Pulmonary Disease Management. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	9
864	Stopping pandemics before they start: Lessons learned from SARS-CoV-2. <i>Science</i> , 2022, 375, 1133-1139.	6.0	58
865	Therapeutic Strategies against Ebola Virus Infection. <i>Viruses</i> , 2022, 14, 579.	1.5	16
866	Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail. <i>Current Opinion in Biotechnology</i> , 2022, 76, 102715.	3.3	5
867	Development and Structural Analysis of Antibody Therapeutics for Filoviruses. <i>Pathogens</i> , 2022, 11, 374.	1.2	7
868	Transient asymptomatic bradycardia and Remdesivir in COVID-19 patients. <i>Minerva Medica</i> , 2022, , .	0.3	1
869	Phosphoramidate Prodrugs Continue to Deliver: The Journey of Remdesivir (GS-5734) from the Liver to Peripheral Blood Mononuclear Cells. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 520-523.	1.3	1

#	ARTICLE	IF	CITATIONS
870	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. <i>Cell</i> , 2022, 185, 995-1007.e18.	13.5	26
872	Recent advances in understanding SARS-CoV-2 infection and updates on potential diagnostic and therapeutics for COVID-19. <i>Coronaviruses</i> , 2022, 03, .	0.2	0
873	Small-molecule HIV-1 entry inhibitors targeting the epitopes of broadly neutralizing antibodies. <i>Cell Chemical Biology</i> , 2022, 29, 757-773.	2.5	4
875	The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. <i>Journal of Personalized Medicine</i> , 2022, 12, 439.	1.1	6
876	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 537-542.	0.6	6
877	Field performance of three Ebola rapid diagnostic tests used during the 2018â€“20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 891-900.	4.6	15
878	Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020. <i>New England Journal of Medicine</i> , 2022, 386, 1188-1191.	13.9	10
879	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010220.	1.3	11
880	Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry. <i>ACS Infectious Diseases</i> , 2022, 8, 942-957.	1.8	6
881	Cocktail party: Low-dose antibody combinations deliver pan-ebolavirus protection. <i>Cell</i> , 2022, 185, 943-945.	13.5	1
882	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. , 2022, 1, .		7
883	Identification of novel Ebola virus inhibitors using biologically contained virus. <i>Antiviral Research</i> , 2022, 200, 105294.	1.9	5
884	The road to effective and accessible antibody therapies against Ebola virus. <i>Current Opinion in Virology</i> , 2022, 54, 101210.	2.6	7
885	The discovery and development of novel treatment strategies for filoviruses. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 139-149.	2.5	9
886	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
887	The direct and indirect effects of bioactive compounds against coronavirus. <i>Food Frontiers</i> , 2022, 3, 96-123.	3.7	17
888	Low Dose Pig Anti-Influenza Virus Monoclonal Antibodies Reduce Lung Pathology but Do Not Prevent Virus Shedding. <i>Frontiers in Immunology</i> , 2021, 12, 790918.	2.2	3
889	Review on Adverse effects or side effects of Remdisivir. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2021, , 162-166.	0.1	2

#	ARTICLE	IF	CITATIONS
891	Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. <i>Pharmaceuticals</i> , 2021, 14, 1272.	1.7	20
893	An Overview of COVID-19 and Its Vaccines. <i>Biology Bulletin Reviews</i> , 2021, 11, 47-64.	0.3	0
894	Current strategies in diagnostics and therapeutics against novel coronavirus disease (COVID-19). <i>Acta Pharmaceutica</i> , 2022, 72, 171-197.	0.9	2
895	Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8141-8158.	3.3	12
896	Protective effects of combining monoclonal antibodies and vaccines against the <i>Plasmodium falciparum</i> circumsporozoite protein. <i>PLoS Pathogens</i> , 2021, 17, e1010133.	2.1	20
897	Ebola Virus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 155-170.	0.8	3
898	COVID-19 Treatment Options and Their Mechanism of Action up to Now: An Overview of Clinical Trials. <i>Journal of Advances in Medical and Biomedical Research</i> , 2022, 30, 75-85.	0.1	1
900	Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. <i>JCI Insight</i> , 2022, 7, .	2.3	18
904	Use of remdesivir in children with COVID-19 infection: a quick narrative review. <i>Acta Biomedica</i> , 2021, 92, e2021524.	0.2	10
905	Discovering trends and hotspots of biosafety and biosecurity research via machine learning. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	1
906	Safety and Tolerability of Remdesivir in Patients with End-stage Renal Disease on Maintenance Hemodialysis. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 619-625.	0.3	3
907	Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. <i>Current Drug Therapy</i> , 2022, 17, .	0.2	0
908	A cryptic pocket in Ebola VP35 allosterically controls RNA binding. <i>Nature Communications</i> , 2022, 13, 2269.	5.8	19
909	Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly. <i>Journal of Biological Chemistry</i> , 2022, 298, 102025.	1.6	4
910	What Do Antibody Studies Tell Us about Viral Infections?. <i>Pathogens</i> , 2022, 11, 560.	1.2	0
911	<scp>Prepared to Act: Lessons Learned by the Special Pathogens Research Network, Based on Collaborations with the NIAID-Led Adaptive COVID-19 </scp> <scp>Treatment Trial</scp>. <i>Health Security</i> , 2022, , .	0.9	2
912	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
913	The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. <i>Archives of Toxicology</i> , 2022, 96, 2341-2360.	1.9	11

#	ARTICLE	IF	CITATIONS
914	Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
915	Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4378-4389.	5.7	5
918	Using Precision Medicine for the Diagnosis and Treatment of Viral Pneumonia. <i>Advances in Therapy</i> , 2022, 39, 3061-3071.	1.3	3
919	Interaction of Ebola Virus with the Innate Immune System. , 0, , .		0
920	Effect of Recombinant Vesicular Stomatitis Virusâ€“Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	4
921	Risk Prediction Score for Pediatric Patients with Suspected Ebola Virus Disease. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	2
922	Pyronaridine Protects against SARS-CoV-2 Infection in Mouse. <i>ACS Infectious Diseases</i> , 2022, 8, 1147-1160.	1.8	14
923	Evaluation of viral load in patients with Ebola virus disease in Liberia: a retrospective observational study. <i>Lancet Microbe</i> , The, 2022, 3, e533-e542.	3.4	4
924	The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6078.	1.8	4
925	FDA Coronavirus Treatment Acceleration Program: approved drugs and those in clinical trials. , 2022, , 249-264.		2
926	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	20
927	Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 2236-2238.	13.9	3
928	Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. <i>Pathogens</i> , 2022, 11, 655.	1.2	5
929	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	21.5	68
931	Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2. , 2022, , 451-488.		0
932	Monoclonal antibodies for diagnostic and therapeutic systems to combat microbial infections. , 2022, , 627-660.		0
933	Operational challenges and considerations for COVID-19 research in humanitarian settings: A qualitative study of a project in Eastern Democratic Republic of the Congo and South Sudan. <i>PLoS ONE</i> , 2022, 17, e0267822.	1.1	3
934	The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. <i>MBio</i> , 2022, 13, .	1.8	10

#	ARTICLE	IF	CITATIONS
935	A Review: Remdesivir and Covid-19. International Journal of Advanced Research in Science, Communication and Technology, 0, , 501-506.	0.0	0
936	Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects. Journal of Cardiovascular Pharmacology, 2022, 80, 616-622.	0.8	1
937	Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond. Cells, 2022, 11, 2198.	1.8	9
938	Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe, The, 2022, 3, e683-e692.	3.4	10
940	Exotic viral hepatitis; a review on epidemiology, pathogenesis, and treatment. Journal of Hepatology, 2022, , .	1.8	5
941	Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold. European Journal of Medicinal Chemistry, 2022, 240, 114608.	2.6	0
942	Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2. PLoS Computational Biology, 2022, 18, e1010330.	1.5	7
943	Avidity in antibody effector functions and biotherapeutic drug design. Nature Reviews Drug Discovery, 2022, 21, 715-735.	21.5	65
944	Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. International Journal of Environmental Research and Public Health, 2022, 19, 8845.	1.2	9
945	Remdesivir-Induced Marked Sinus Bradycardia in COVID-19. Cureus, 2022, , .	0.2	0
946	Neuropilin-1 in the pathogenesis of preeclampsia, HIV-1, and SARS-CoV-2 infection: A review. Virus Research, 2022, 319, 198880.	1.1	5
947	Pregnancy outcomes with coronavirus pregnancy outcomes with coronavirus infection (COVID-19). Acta Facultatis Medicae Naissensis, 2022, 39, 117-140.	0.1	0
948	The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps. Vaccines, 2022, 10, 1213.	2.1	11
950	Inclusion of pregnant and breastfeeding women in nonobstetrical randomized controlled trials. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100700.	1.3	8
952	Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study. Journal of Medical Virology, 2022, 94, 5702-5712.	2.5	7
953	Severe <sc>SARS-CoV</sc> 2 infection in a 32-week pregnant woman treated with Remdesivir&Dexamethasone combination therapy: A case report. Clinical Case Reports (discontinued), 2022, 10, .	0.2	3
954	A drug-disease model for predicting survival in an Ebola outbreak. Clinical and Translational Science, 2022, 15, 2538-2550.	1.5	4
955	A multifaceted high-throughput assay for probing antigen-specific antibody-mediated primary monocyte phagocytosis and downstream functions. Journal of Immunological Methods, 2022, 510, 113328.	0.6	3

#	ARTICLE	IF	CITATIONS
956	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
957	Role of Siglecs in viral infections: A double-edged sword interaction. <i>Molecular Aspects of Medicine</i> , 2022, , 101113.	2.7	5
958	Honey as an Adjuvant in the Treatment of COVID-19 Infection: A Review. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 7800.	1.3	6
959	Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4907-4920.	1.6	5
960	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. <i>Vaccines</i> , 2022, 10, 1384.	2.1	3
961	Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
962	Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies. <i>EBioMedicine</i> , 2022, 82, 104186.	2.7	1
963	Tecovirimat and the Treatment of Monkeypox “ Past, Present, and Future Considerations. <i>New England Journal of Medicine</i> , 2022, 387, 579-581.	13.9	106
964	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
965	Translational pharmacokinetics of a novel bispecific antibody against Ebola virus (MBS77E) from animal to human by PBPK modeling & simulation. <i>International Journal of Pharmaceutics</i> , 2022, 626, 122160.	2.6	2
966	Virus kinetics and biochemical derangements among children with Ebolavirus disease. <i>EClinicalMedicine</i> , 2022, 53, 101638.	3.2	1
967	Nutraceutical prospects of <i>Houttuynia cordata</i> against the infectious viruses. <i>Food Bioscience</i> , 2022, 50, 101977.	2.0	7
968	Potential drugs in SARS-CoV-2 treatment. , 2022, , 59-71.		0
969	Management of COVID-19 During Pregnancy and the Postpartum Period. , 2022, , 319-342.		0
970	Nanocarriers as delivery tool for COVID-19 drugs. , 2022, , 293-332.		1
971	Maternal Health in Low Resource Settings. <i>Advances in Medical Education, Research, and Ethics</i> , 2022, , 109-140.	0.1	0
972	COVID-19 and Cardiovascular Manifestations. , 2022, , 102-136.		0
973	Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues. <i>Advanced Science</i> , 2022, 9, .	5.6	11

#	ARTICLE	IF	CITATIONS
974	Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
976	The Diagnostic Accuracy of Rapid Diagnostic Tests for Ebola Virus Disease: a Systematic Review. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	0
977	Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. <i>Cancers</i> , 2022, 14, 4720.	1.7	9
978	A counterintuitive antibody cocktail disrupts coxsackievirus. <i>Cell Host and Microbe</i> , 2022, 30, 1194-1195.	5.1	1
979	Structure of the Ebola virus polymerase complex. <i>Nature</i> , 2022, 610, 394-401.	13.7	22
981	Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep. <i>Gene Therapy</i> , 0, , .	2.3	6
982	Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	20
983	Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
984	Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828.	0.6	0
985	Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program. <i>Journal of Clinical Pharmacology</i> , 0, , .	1.0	6
986	Development and optimization of biologically contained Marburg virus for high-throughput antiviral screening. <i>Antiviral Research</i> , 2022, 207, 105426.	1.9	1
987	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 85-114.	0.1	0
988	Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211327.	1.0	3
989	Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review. <i>Indian Journal of Dermatopathology and Diagnostic Dermatology</i> , 2022, 9, 47.	0.0	0
991	Use of Remdesivir in severe COVID-19 Pregnant Patient. <i>Journal of Research & Innovation in Anesthesia</i> , 2022, 7, 56-58.	0.0	0
993	The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010889.	1.3	6
994	Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
995	An introduction to the Marburg virus vaccine consortium, MARVAC. <i>PLoS Pathogens</i> , 2022, 18, e1010805.	2.1	22

#	ARTICLE	IF	CITATIONS
997	Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients. Wiener Klinische Wochenschrift, 2022, 134, 883-891.	1.0	5
998	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Life, 2022, 12, 1758.	1.1	9
999	Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo. EClinicalMedicine, 2022, 54, 101699.	3.2	2
1000	V. Current Treatment Approach for COVID-19. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2374-2382.	0.0	0
1001	DÄ©jÄ vu all over again? Monkeypox and the urgent need for randomised controlled trials. Lancet Infectious Diseases, The, 2022, , .	4.6	6
1003	Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). Journal of Clinical Medicine, 2022, 11, 6545.	1.0	4
1004	Plant-based expression platforms to produce high-value metabolites and proteins. Frontiers in Plant Science, 0, 13, .	1.7	6
1005	Preparing for pandemics: a systematic review of pandemic influenza clinical management guidelines. BMC Medicine, 2022, 20, .	2.3	3
1006	Triage of patients with Ebola virus disease. Lancet Infectious Diseases, The, 2023, 23, 10-12.	4.6	1
1007	The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antiviral Research, 2023, 209, 105453.	1.9	4
1008	Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir. Microbiology Spectrum, 2022, 10, .	1.2	2
1009	Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model. Antiviral Research, 2022, 208, 105462.	1.9	3
1010	Improving combination drug trials using â€˜definitive screening designsâ€™™. Nature Biotechnology, 0, , .	9.4	0
1011	Filoviruses and Arenaviruses. , 2023, , 1213-1219.e2.		0
1012	Antiviral Treatment of COVID-19 Pneumonia. Clinics in Chest Medicine, 2022, , .	0.8	0
1013	Filoviruses: Innate Immunity, Inflammatory Cell Death, and Cytokines. Pathogens, 2022, 11, 1400.	1.2	4
1014	Advancing detection and response capacities for emerging and re-emerging pathogens in Africa. Lancet Infectious Diseases, The, 2023, 23, e185-e189.	4.6	4
1016	Management of Coronavirus Disease-2019 Infection in Pregnancy. Emergency Medicine Clinics of North America, 2023, 41, 307-322.	0.5	0

#	ARTICLE	IF	CITATIONS
1017	Bayesian Strategies in Rare Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2023, 57, 445-452.	0.8	3
1018	Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	3
1019	Use of Antiviral Agents and other Therapies for COVID-19. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 118-129.	0.8	3
1020	Efficiency of Field Laboratories for Ebola Virus Disease Outbreak during Chronic Insecurity, Eastern Democratic Republic of the Congo, 2018â€“2020. <i>Emerging Infectious Diseases</i> , 2023, 29, 1-9.	2.0	1
1021	Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. <i>Heliyon</i> , 2023, 9, e12667.	1.4	0
1022	Efficiency of Field Laboratories for Ebola Virus Disease Outbreak during Chronic Insecurity, Eastern Democratic Republic of the Congo, 2018â€“2020. <i>Emerging Infectious Diseases</i> , 2023, 29, 1-9.	2.0	2
1023	Viral infections in critical care: a narrative review. <i>Anaesthesia</i> , 0, , .	1.8	1
1024	A Recent Update on SARS-CoV-2 Transmission and its Variants: Transmission, Pathogenic Mechanism, and Treatment. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
1025	Of mice and Mikeâ€”An underappreciated Ebola virus disease model may have paved the road for future filovirology. <i>Antiviral Research</i> , 2023, 210, 105522.	1.9	1
1026	Experience of Using Remdesivir in Patients with Novel Coronavirus Infection. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 365-380.	0.1	0
1027	Global Ophthalmic Health Initiatives in Ebola and Emerging Infectious Disease Outbreaks: Implications for Vision Health Systems, Program Implementation, and Disease Surveillance. <i>International Ophthalmology Clinics</i> , 2023, 63, 79-89.	0.3	0
1028	Breakthrough treatments for Ebola virus disease, but no accessâ€”what went wrong, and how can we do better?. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e253-e258.	4.6	8
1029	The Continuing Puzzle of Defining Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
1030	Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus disease. <i>Southern African Journal of Infectious Diseases</i> , 2023, 38, .	0.3	0
1031	On the importance and challenges of global access to proven life-saving treatments for Ebolavirus â€” Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 407-408.	4.6	0
1032	The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	7
1033	Structure of the Inmazeb cocktail and resistance to Ebola virus escape. <i>Cell Host and Microbe</i> , 2023, 31, 260-272.e7.	5.1	11
1034	Structural basis for substrate selection by the SARS-CoV-2 replicase. <i>Nature</i> , 2023, 614, 781-787.	13.7	14

#	ARTICLE	IF	CITATIONS
1035	Global landscape of randomized controlled trials responding to the COVID-19 pandemic: a literature review protocol. <i>F1000Research</i> , 0, 12, 133.	0.8	0
1036	Drugs swapping in coronavirus strains: a structural biology view. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13488-13495.	2.0	1
1037	Standard of care for viral haemorrhagic fevers (VHFs): a systematic review of clinical management guidelines for high-priority VHFs. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e240-e252.	4.6	3
1038	Therapeutic options in COVID-19. , 2023, , 647-672.		0
1039	How to use COVID-19 antiviral drugs in patients with chronic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
1040	Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. <i>JAMA Network Open</i> , 2023, 6, e2255815.	2.8	2
1041	The use of Remdesivir in pregnant women with COVID-19. <i>Journal of Clinical Medicine of Kazakhstan</i> , 2023, 20, 31-34.	0.1	0
1042	Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A retrospective cohort study. <i>Current Drug Therapy</i> , 2023, 18, .	0.2	0
1043	Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. <i>Molecules</i> , 2023, 28, 2332.	1.7	6
1044	Ebangaâ„¢: The most recent FDA-approved drug for treating Ebola. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1045	SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	15
1046	Role of TGF-Î² Signaling in Coronavirus Disease 2019. , 2022, 9, 9.		1
1047	The West Africa Lassa fever Consortium pre-positioned protocol for a Phase II/III adaptive, randomised, controlled, platform trial to evaluate multiple Lassa fever therapeutics. <i>Wellcome Open Research</i> , 0, 8, 122.	0.9	1
1048	On the importance and challenges of global access to proven life-saving treatments for Ebolavirus. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 406-407.	4.6	0
1049	Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	1
1050	Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. <i>IScience</i> , 2023, 26, 106540.	1.9	2
1051	Specialty grand challenge editorial innovative approaches for pharmacoepidemiologic research in pregnancy: Shifting the paradigm of Thalidomideâ€™s impact on pregnant women. <i>Frontiers in Drug Safety and Regulation</i> , 0, 3, .	0.5	0
1052	Impact of Maternal SARS-CoV-2 Infection on the Fetus and Newborn. , 2024, , 235-252.		0

#	ARTICLE	IF	CITATIONS
1053	Emerging Pandemic Infectious Disease Threats. , 2023, , 399-411.		0
1054	Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves. <i>Viruses</i> , 2023, 15, 947.	1.5	2
1055	Modulation of <i>in Vitro</i> SARS-CoV-2 Infection by <i>Stephania tetrandra</i> and Its Alkaloid Constituents. <i>Journal of Natural Products</i> , 2023, 86, 1061-1073.	1.5	2
1056	Head-to-head comparison of diagnostic accuracy of four Ebola virus disease rapid diagnostic tests versus GeneXpert [®] in eastern Democratic Republic of the Congo outbreaks: a prospective observational study. <i>EBioMedicine</i> , 2023, 91, 104568.	2.7	2
1057	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
1058	Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. <i>Infectious Diseases and Therapy</i> , 2023, 12, 1189-1203.	1.8	6
1059	Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1060	New targets for old drugs. , 2023, , 315-349.		0
1068	Application of approved and marketed products of monoclonal antibody therapies. , 2023, , 287-327.		0
1085	Promising Schiff bases in antiviral drug design and discovery. <i>Medicinal Chemistry Research</i> , 2023, 32, 1063-1076.	1.1	12
1098	Ebola Vaccines. , 2023, , 311-329.e6.		0
1099	Passive Immunization. , 2023, , 100-112.e11.		0
1100	VEKLURY [®] (REMDESIVIR), A NUCLEOTIDE PRODRUG APPROVED FOR THE TREATMENT OF COVID-19. <i>Medicinal Chemistry Reviews</i> , 0, , 545-569.	0.1	1
1101	Ethics and Tropical Diseases: Some Global Considerations. , 2024, , 64-69.		0
1109	Hepatitis, viral. , 2023, , .		0
1119	Meta-Analysis of Spread of Disease: COVID-19*. , 2023, , .		0
1128	Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention. <i>Pediatric Research</i> , 2024, 95, 488-495.	1.1	1
1134	Ethics of Placebo-Controlled Trials: Historical Analysis Including Experiences During the COVID-19 Pandemic. , 2023, , 195-224.		0

#	ARTICLE	IF	CITATIONS
1146	Role of miRNA in Ebola diagnosis and therapeutics. , 2024, , 135-163.		0
1149	SARS-CoV-2 und andere neu auftretende Virusinfektionen. Springer Reference Medizin, 2024, , 1-9.	0.0	0
1151	Ebola and Marburg viruses. , 2024, , 2281-2308.		0
1152	Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches. Infectious Diseases and Therapy, 2024, 13, 21-55.	1.8	2